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Validation of the Functional Assessment of Cancer Therapy Cognitive Scale
with Bone Marrow Transplant Patients
Sheri R. Jacobs
ABSTRACT
Research has demonstrated that cancer patients report problems with cognitive
functioning related to their cancer and their cancer treatments. Cognitive complaints
refer to subjective reports of problems such as decreased memory, attention,
concentration, and language skills. These problems with cognitive functioning can
interfere with a person’s quality of life. The current measures of cognitive complaints
have poor or unknown psychometric properties. Therefore, the present study sought to
examine the psychometric properties of a newly developed measure of cognitive
complaints for cancer patients, the Functional Assessment of Cancer Therapy Cognitive
Scale (FACT-Cog). Eighty-two patients were administered a comprehensive battery of
neuropsychological tests assessing memory, executive functioning, motor, and attention,
as well as a battery of psychosocial measures six months or twelve months after receiving
a bone marrow transplant. Results indicated that the internal consistency reliability of the
FACT-Cog was high. Concurrent validity was evidenced by the significant relationship
of the FACT-Cog to another measure of cognitive complaints. Convergent validity is
evidenced by the significant relationship of the FACT-Cog to measures of depression,
fatigue, anxiety, mental well-being, and physical well-being. Divergent validity was
evidenced by the lack of significant relationship of the FACT-Cog to a measure of
extroversion. In contrast, there was limited support for the criterion validity of the
iv

FACT-Cog as evidenced by the limited significant relationships with neuropsychological
test scores. The FACT-Cog did not demonstrate superior psychometric properties to an
existing measure of cognitive complaints (EORTC-CF). Future research should
investigate the relationship of cognitive complaints to cognitive performance utilizing
longitudinal designs, other clinical populations, and neuropsychological tests that require
sustained effort.

v

Introduction
Cognitive functioning among adult cancer patients has received increasing
attention in recent years. Research suggests that problems with cognitive functioning
have a large impact on quality life, interfere with the ability to function in daily
activities, and affect educational and career choices. Therefore, it is important to
correctly identify and assess problems associated with cognitive functioning. Cognitive
functioning has been assessed in two ways: by measuring cognitive performance on
standardized neuropsychological tests and by obtaining self-reports of cognitive
complaints. Although methodology for assessing cognitive performance is fairly well
developed, the same cannot be said for the assessment of cognitive complaints. Current
methods for measuring cognitive complaints either lack sound psychometric properties
or have unknown psychometric properties. Recognizing the need for a reliable and valid
measure, Wagner, Sweet, Cella, and Doninger (2002) have developed the Functional
Assessment of Cancer Therapy Cognitive Scale (FACT-Cog). This measure of
cognitive complaints is composed of behaviorally-based items in an effort to minimize
the impact of distress unrelated to cognitive abilities. The aim of the present study was
to examine the psychometric properties of this newly developed instrument using bone
marrow transplantation (BMT) patients as the validation sample.
The following section will evaluate different methods of measuring cognitive
functioning in cancer patients. First, studies assessing cognitive complaints but not
cognitive performance in cancer patients will be discussed. Next, studies assessing both
cognitive complaints and cognitive performance will be reviewed. Finally, the
development and structure of the FACT-Cog will be discussed.
1

Review of Cognitive Complaints Literature
Although there is no consensus, cognitive complaints typically refers to subjective
difficulties with memory, attention, concentration, and language skills (Olin, 2001).
Cognitive complaints, such as difficulties with attention and concentration, may overlap
with symptoms of depression and fatigue. However, unlike depression and fatigue,
cognitive complaints can include problems with mental acuity, verbal and nonverbal
memory, verbal fluency, and the impact of decreased cognitive abilities on a person’s
functioning and quality of life. Although there is overlap among depression, fatigue, and
cognitive complaints it is possible to distinguish them, and anecdotally patients report
cognitive complaints without experiencing depression or fatigue. This highlights the
importance of reliably and validly measuring cognitive complaints.
A variety of methods have been used to assess cognitive functioning in cancer
survivors. Some studies have relied on subjective measures to assess cognitive
complaints without using objective measures of cognitive performance. Five such studies
can be identified. Two studies used the Sickness Impact Profile (SIP) Alertness Behavior
Scale (Bergner, Bobbitt, Carter, & Gilson, 1981) and the Profile of Mood State (POMS)
Confusion Scale (McNair, Lorr, & Droppleman, 1971) and three studies used the
European Organization for Research and Treatment of Cancer – Quality of life
Questionaire-C30 Cognitive Functioning Scale (EORTC-CF; Aaronson, Ahmedzai,
Bergman, Bullinger, & Cull, 1993) to assess cognitive complaints.
The first study, by Andrykowski, Henslee, and Barnett (1989), used the SIP
Alertness Behavior Scale and the POMS Confusion Scale to assess cognitive complaints.
The SIP Alertness Behavior Scale consists of ten items assessing the presence of
2

difficulties in memory, attention, and concentration. Higher scores indicate greater
dysfunction. The POMS Confusion Scale consists of seven descriptors, such as,
‘confused’, ‘unable to concentrate’, ‘muddled’, and ‘efficient’. Respondents indicate for
the last week the degree to which each descriptor is characteristic of them. Higher scores
indicate greater dysfunction. In this study, 16 allogeneic BMT patients were assessed
two years following transplant and then again at four years post-transplant. Scores on the
SIP Alertness Behavior Scale improved significantly from time one to time two. Scores
at both assessments reflected more impairment in comparison to scores from a sample of
renal implant patients and scores from a sample of chronic peritoneal dialysis patients.
Scores on the POMS Confusion Scale remained stable across time and were similar to
scores from the comparison samples.
A second study by Andrykowski et al. (1990) also assessed cognitive complaints
using the SIP Alertness Behavior Scale and the POMS Confusion Scale. Thirty
allogeneic BMT patients were divided into three groups based on the amount of Total
Body Irradiation (TBI) they had received: patients who received 900 cGy or less (N=13),
patients who received 1200 cGy (N=9), and patients who received 1320 or 1400 cGy
(N=8). After controlling for age, time post-BMT, education, and current psychological
distress, the SIP Alertness Behavior Scale was found to be significantly positively related
to TBI dose. The correlation between the POMS Confusion Scale and TBI dose only
approached significance.
Joly et al. (1998) used the EORTC-CF to assess cognitive complaints. The
EORTC-CF consists of two items rated on a four-point scale (1=Not at all, 2=A little,
3=Quite a bit, 4=Very much). One item assesses difficulty with concentration and the
3

other item assesses difficulty with memory. The sample in this study consisted of men
with localized prostate cancer (N=71) and healthy controls (N=71). The prostate cancer
patients were tested an average of four years post-treatment. No significant difference
was found on the EORTC-CF between patients and controls.
Hjermstad, Holte, Evensen, Fayers, and Kaasa (1999) also administered the
EORTC-CF to measure cognitive complaints. The samples of cancer patients consisted
of leukemia patients treated with high-dose chemotherapy and allogeneic BMT (N=41),
lymphoma patients treated with high-dose chemotherapy and autologous BMT (N=51),
and lymphoma patients treated with combination chemotherapy (N=85). Lymphoma
patients who underwent autologous BMT reported significantly greater cognitive
complaints than the other two cancer groups and the healthy controls. No significant
differences existed between the leukemia patients treated with allogeneic BMT, the
lymphoma patients treated with combination chemotherapy or the healthy controls.
Green, Pakenham, Headley, and Gardiner (2002) used the EORTC-CF to measure
cognitive complaints in 65 prostate cancer patients at baseline and 6 months posttreatment and 16 healthy controls over a similar time interval. As part of their cancer
treatment, prostate cancer patients were randomized to an observation group or a
hormonal therapy group. There was no significant difference in EORTC-CF scores
between the observation group and the hormonal therapy group. There was also no
significant change in scores from time one to time two in either group. As predicted,
higher threat appraisal at baseline was significantly correlated with greater cognitive
complaints at baseline and at 6 months. Contrary to the authors’ prediction that greater
use of emotion or problem-focused coping would be correlated with lower levels of
4

cognitive complaints, greater use of coping at baseline was significantly correlated with
higher levels of cognitive complaints at 6 months.
In summary, evaluation of group differences provides limited support for the
validity of the cognitive complaint measures. Findings indicating that, as TBI dose for
allogeneic BMT patients increased, scores of the SIP Alertness Behavior Scale also
increased (Andrykowski et al., 1990) would be expected and, therefore, support the
validity of the SIP Alertness Behavior Scale. However, findings indicating that scores on
the SIP Alertness Behavior Scale worsened significantly for allogeneic BMT patients
from two years post-transplant to four years post-transplant (Andrykowski et al., 1989)
are contrary to what would be expected. Therefore, this finding does not support the
validity of the SIP Alertness Behavior Scale.
Findings indicating that the correlation between the POMS Confusion Scale and
TBI dose approached significance (Andrykowski et al., 1990) would be expected and
provide partial support for the validity of the POMS Confusion Scale. However, findings
indicating that scores on the POMS Confusion Scale were stable over time from two
years post-transplant to four years post-transplant (Andrykowski et al., 1989) are not
what would be expected. Rather, it would be expected that scores would decrease from
two years to four years post-transplant. This finding does not support the validity of the
POMS Confusion Scale.
Evidence regarding the validity of the EORTC-CF is also mixed. Findings
indicating that lymphoma patients treated with autologous BMT scored significantly
higher on the EORTC-CF than lymphoma patients treated with combination
chemotherapy and a group of healthy controls (Hjermstad et al., 1999) would be expected
5

and, therefore, support the validity of the EORTC-CF. However in the same study,
autologous BMT patients reported greater cognitive complaints on the EORTC-CF than
allogeneic BMT patients (Hjermstad et al., 1999). This finding is contrary to what would
be expected given the better outcomes usually associated with autologous BMT than
allogeneic BMT and, therefore, does not support the validity of the EORTC-CF. Also in
the same study, EORTC-CF scores were not significantly different for leukemia patients
treated with allogeneic BMT, lymphoma patients treated with combination
chemotherapy, and a group of healthy controls (Hjermstad et al., 1999). This finding
does not support the validity of the EORTC-CF because group differences would be
expected between the different treatment groups and the healthy controls. In another
study, EORTC-CF scores were not different for localized prostate cancer patients and
healthy controls (Joly et al., 1998). Again, it would be expected that prostate cancer
patients would score higher on the EORTC-CF than healthy controls and, therefore, the
validity of the EORTC-CF is not supported. No significant differences in EORTC-CF
scores were found between prostate cancer patients receiving hormonal therapy and
prostate cancer patients not receiving hormonal therapy (Green et al., 2002). Group
differences would be expected, with prostate cancer patients receiving hormonal therapy
reporting greater cognitive complaints than prostate cancer patients not receiving
hormonal therapy. Therefore, this finding does not provide support for the validity of the
EORTC-CF.
Other findings reported in these studies also provide mixed evidence regarding
the validity of the cognitive complaint measures. Two studies (Andrykowski et al., 1989,
1990) used two measures of cognitive complaints, the SIP Alertness Behavior Scale and
6

the POMS Confusion scale. The SIP Alertness Behavior Scale was positively correlated
with TBI dose and the POMS Confusion Scale approached significance with TBI dose
(Andrykowski et al., 1990), providing partial support for the concurrent validity of the
two measures. The correlation between the SIP Alertness Behavior Scale and the POMS
Confusion Scale was not reported. Concurrent validity was not supported in another
study (Andrykowski et al., 1989), in which the SIP Alertness Behavior Scale detected
change over time, while the POMS Confusion Scale remained stable over time. Again,
the correlation between the SIP Alertness Behavior Scale and the POMS Confusion Scale
was not reported. In the three studies which used the EORCT-CF (Green et al., 2002;
Hjermstad et al., 1999; Joly et al., 1998), no other measure of cognitive complaints was
used, therefore, concurrent validity is unknown.
Convergent validity was not demonstrated in any of the five previously mentioned
studies (Andrykowski et al., 1989, 1990; Green et al., 2002; Hjermstad et al., 1999; Joly
et al., 1998), as none of the cognitive complaint measures were compared to measures of
constructs such as depression, fatigue, anxiety, and health-related quality of life. One
study (Green et al., 2002) did look at cognitive complaints, measured by the EORTC-CF,
in relation to threat appraisal and coping. As hypothesized by Green et al. (2002), greater
threat appraisal was associated with more cognitive complaints. However, contrary to
expectations, greater not lesser use, of coping was correlated with higher cognitive
complaints.
As none of these studies used neuropsychological tests, criterion validity was not
examined. Also, none of the studies reported internal consistency for the scales. As the
EORTC-CF consists of only two items, internal consistency may be poor.
7

Review of Cognitive Complaints and Cognitive Functioning Literature
In contrast to the studies described previously that assessed only subjective
complaints, eight studies can be identified that used a measure of cognitive complaints as
well as a neuropsychological test battery to assess cognitive functioning. To measure
cognitive complaints, one study used the Medical Outcomes Study (MOS) Cognitive
Functioning Scale (Stewart & Ware, 1992), one study used the Squire Memory SelfRating Questionnaire (Squire, Wetzel, & Slater, 1979), one study used the Concentration
scale of the Checklist Individual Strength (CIS), the Alertness and Intellectual scales of
the SIP, and daily complaints of memory and concentration (Vercoulen et al., 1994), and
five studies used the EORTC-CF. Of the five studies that used the EORTC-CF, three
also used a checklist of cognitive problems in daily life, and one also used an interviewbased rating by a neuropsychologist to assess cognitive complaints.
Klein et al. (2002) used the Cognitive Functioning Scale of the MOS to assess
cognitive complaints. The MOS Cognitive Functioning Scale consists of six items
adapted from the SIP that assess confusion, concentration and thinking, attention,
memory, reasoning, and psychomotor function. Each question is rated on a six-point
Likert-type scale (1=All of the time, 2=Most of the time, 3=A good bit of the time,
4=Some of the time, 5=A little of the time, 6=None of the time). The study sample
consisted of patients with glioma who had been treated with radiotherapy (N=104),
patients with glioma who had not been treated with radiotherapy (N=91), and patients
with hematological cancer (N=100). Neuropsychological measures tested the domains of
intelligence, perception and psychomotor speed, attention and executive function, and
memory. Glioma patients treated with radiotherapy and without radiotherapy reported
8

significantly lower scores on the MOS Cognitive Functioning Scale than published data
on healthy controls, but did not differ from patients with hematological cancer. No
difference was found on the MOS Cognitive Functioning Scale between glioma patients
treated with or without radiotherapy. Among glioma patients, scores on measures of
memory, attention, psychomotor speed, and graphomotor speed were moderately
correlated with cognitive complaints (r = .23, .30, 34, and .31, respectively).
Ahles et al. (2002) used the Squire Memory Self-Rating Questionnaire to measure
cognitive complaints in cancer patients five years post-treatment. The Squire Memory
Self-Rating Questionnaire consists of 18-items rated on a nine-point scale ranging from –
4 (worse than ever before) to +4 (better than ever before). Each item inquires about a
different aspect of memory functioning and was derived from remarks the scale
developers obtained from patients treated with electroconvulsive therapy. The sample in
this study consisted of breast cancer patients treated with chemotherapy (N=35),
lymphoma patients treated with chemotherapy (N=36), breast cancer patients treated with
local therapy (N=35), and lymphoma patients treated with local therapy (N=22). Each
patient was administered neuropsychological tests assessing verbal ability, spatial ability,
verbal learning, verbal memory, visual memory, psychomotor function, motor
functioning, attention, and attention reaction time. Factor analysis of the Squire Memory
Self-Rating Questionnaire yielded three factors: new learning, working memory, and
remote retrieval. The factor of working memory was found to be significantly lower for
patients treated with chemotherapy than local therapy. The correlation between the
factors and the neuropsychological domains were described as generally low and
nonsignificant (values not reported).
9

Servaes, Verhagen, and Bleinjenberg (2002) used three instruments to assess
cognitive complaints: the Concentration scale of the CIS, the Alertness and Intellectual
scales of the SIP, and a daily record of complaints about memory and concentration. The
CIS Concentration scale consists of five items scored on a seven-point Likert scale with
higher scores indicating a higher level of concentration problems. To determine daily
complaints of memory and concentration, patients were asked to keep a self-observation
list for a 12-day period. Memory and concentration problems were rated four times daily
(0=No, 1=Yes). Total daily scores ranged from 0 to 4, with high scores indicating more
problems with memory and concentration. The sample consisted of 150 breast cancer
patients who were divided into two groups, severely fatigued patients (n=57) and
nonseverely fatigued patients (n=93). Patients were defined as severely fatigued if they
scored 35 or higher on the Fatigue Severity Scale of the CIS. Data were also collected
for a control group of 78 friends and family of the breast cancer patients with no history
of cancer. Patients were tested six months to five years post-treatment. The treatments
patients received consisted of radiotherapy and chemotherapy (N=66), no chemotherapy
or radiotherapy (N=20), chemotherapy only (N=33), or radiotherapy only (N=31).
Neuropsychological tests assessed reaction time and concentration. With one exception,
severely fatigued breast cancer patients reported significantly more problems on all three
measures of cognitive complaints than the nonseverely fatigued breast cancer patients
and controls. The exception was for daily reports of memory problems, in which no
difference was seen between severely and nonseverely fatigued patients. Nonseverely
fatigued patients did not differ from controls on any measure of cognitive complaints.
No significant differences in cognitive complaints existed between the different treatment
10

groups. Severely fatigued, nonseverely fatigued, and controls did not differ on
neuropsychological tests of concentration. However, for reaction time, group differences
did exist. Severely fatigued patients were significantly slower compared to controls, but
severely fatigued patients were not significantly different than nonseverely fatigued
patients. Nonseverely fatigued patients had slower reaction times than the controls for
one of the three reaction time subtests. The lack of differences between severely fatigued
patients and nonseverely fatigued patients on a concentration task and a reaction time
task are not consistent with the subjective reports, where severely fatigued patients had
greater complaints than the nonseverely fatigued patients.
Cull, Hay, Love, Mackie, Smets, and Stewart (1996) used the EORTC-CF to
measure cognitive complaints in 91 lymphoma patients six months post-treatment. The
EORTC-CF was used to divide the sample into complainers (N=25) and non-complainers
(N=66), which was defined as rating either question a “3” or a “4”. Neuropsychological
measures were used to test intelligence, concentration, and memory. Complainers and
non-complainers did not differ significantly on the neuropsychological measures of
intelligence, memory, and concentration. No significant difference was found between
complainers and non-complainers on ratings of their health and global quality of life,
however, complainers had significantly higher scores on measures of anxiety, depression,
and fatigue than non-complainers.
Van Dam et al. (1998) used the EORTC-CF and a checklist of cognitive
complaints in daily life to measure cognitive complaints. The checklist consisted of four
questions assessing concentration, memory, thinking, and language. Patients were asked
to indicate the extent to which problems in each of these four domains occurred in their
11

daily life on a five-point Likert scale (0=Not at all, 1=Slightly, 2=Moderately, 3=Quite a
bit, 4=Extremely). The sample consisted of 70 patients two years post-treatment who had
been randomly assigned to receive high-dose chemotherapy (N=34) or standard-dose
chemotherapy (N=36) and a control group of breast cancer patients matched on age and
time since treatment who had not received chemotherapy (N=34). Patients were assessed
with neuropsychological measures of verbal function, memory, attention/concentration,
speed of information processing, motor function, visuoconstructional function, and
mental flexibility. An overall score of cognitive impairment (OSCI) was calculated for
each patient by counting all tests on which the patient was impaired. Impairment was
defined for the chemotherapy groups as scoring two standard deviations below the mean
score of the control group on that test. Impairment for the control group was defined as
scoring in the fifth percentile of the control patients for that test. On the checklist, the
high-dose and standard-dose chemotherapy groups did not significantly differ from each
other. Both chemotherapy groups scored significantly higher than the control group for
complaints on the checklist items related to concentration, memory, and language. For
the EORTC-CF there was no significant difference between the two chemotherapy
groups, and only the high-dose chemotherapy group scored significantly higher than the
control group. The checklist and the EORTC-CF were significantly correlated with each
other. The EORTC-CF and the checklist concentration, memory, and thinking questions
were also significantly correlated with measures of anxiety and depression. No
relationship existed between either measure of cognitive complaints and the OSCI (range
r = -.03 to .08).
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Schagen et al. (1999) used the same measures of cognitive complaints as van Dam
et al. (1998) to assess breast cancer patients two years post-treatment. The sample in this
study consisted of patients who were treated with conventional chemotherapy (N=39) and
the control group from the van Dam et al. (1998) study (N=34). These patients received
the same neuropsychological measures as in the previously discussed study and
impairment was also defined in the same way. On the checklist, the chemotherapy
patients reported significantly more complaints in concentration and memory than the
control group. No significant group differences existed for the checklist items about
thinking and language. Chemotherapy patients scored significantly higher on the
EORTC-CF than the healthy controls. Scores on the checklist and on the EORTC-CF
were not significantly related to the OSCI or to any of the domain scores of the
neuropsychological tests (range r = -.20 to .08). The checklist and the EORTC-CF were
significantly correlated with each other and with measures of anxiety and depression.
Schagen et al. (2002) reassessed the samples from the van Dam et al. (1998) study
and the Schagen et al. (1999) study two years after the initial testing using the same
cognitive complaints measures and neuropsychological measures. The sample consisted
of three groups: high-dose and standard-dose chemotherapy patients (N=45) from the van
Dam et al. study (1998); conventional chemotherapy patients (N=31) from the Schagen et
al. study (1999), and the control group used in both previously mentioned studies (N=27).
At four years post-treatment there were no significant differences in scores on the
checklist and scores on the EORTC-CF among the high-dose group, the standard-dose
group, and the control group. Patients in the conventional chemotherapy group reported
significantly more cognitive complaints than the control group on the checklist questions
13

of concentration and memory and on the EORTC-CF. The correlations between
cognitive performance and cognitive complaints for all groups were low and
nonsignificant (range r =.19-.22). The relationship between the changes in cognitive
performance and the changes in cognitive complaints assessed by the checklist was
characterized as negligible.
Harder et al. (2002) used the EORTC-CF and a rating by a neuropsychologist to
measure cognitive complaints in 40 patients who had completed allogeneic BMT 22 to 82
months earlier. Based on an interview, the neuropsychologist rated the extent of the
patient’s cognitive problems on a four-point Likert-type scale (0=no problem, 1=mild
problems, 2=moderate problems, 3=severe problems). Patients were assessed on
neuropsychological measures of general intelligence and conceptual reasoning, verbal
function, memory, attention functions and concentration, executive functions, visual
spatial and visuoconstructive ability, psychomotor function, and speed of information
processing. The EORTC-CF was significantly positively correlated with fatigue. Total
neuropsychological impairment, defined as the number of tests the patient scored two
standard deviations below healthy population norms, was significantly negatively
correlated with the EORTC-CF (r = -.55). There was no relationship between total
neuropsychological impairment and the neuropsychologist’s rating (values not reported).
In summary, studies evaluating group differences yield mixed support for the
validity of each cognitive complaint measure. For the one study that used the MOS
Cognitive Functioning Scale (Klein et al., 2002), glioma patients treated with or without
radiotherapy reported significantly greater cognitive complaints in comparison to
published data on healthy controls. The finding that glioma patients reported greater
14

cognitive complaints is consistent with expectations, providing support for the validity of
the MOS Cognitive Functioning Scale. However, the MOS Cognitive Functioning Scale
did not detect group differences between the glioma patients treated with radiotherapy,
the glioma patients treated without radiotherapy, and the patients with hematological
cancer. As group differences would be expected, these findings do not support the
validity of the MOS Cognitive Functioning Scale.
In the one study that used the Squire Memory Self-Rating Questionnaire (Ahles et
al., 2002), one of the three factors of the questionnaire (working memory) was
significantly lower for breast cancer patients treated with chemotherapy than breast
cancer patients treated with local therapy. This finding would be expected and, therefore,
supports the validity of the working memory factor of the Squire Memory Self-Rating
Questionnaire. However, no group differences were found for the other two factors of
new learning and remote retrieval. Taken together, these findings provide very limited
support for the validity of this measure.
Severely fatigued breast cancer patients were found to score significantly higher
on the CIS, SIP Alertness Intellectual scales, and ratings of daily complaints of memory
or concentration than nonseverely fatigued breast cancer patients and healthy controls
(Servaes et al., 2002). These results are consistent with the expectation that severely
fatigued patients would have the most cognitive complaints, and provides support for the
validity of the CIS, SIP Alertness Intellectual scales, and ratings of daily complaints of
memory or concentration. Findings also indicated that scores on the CIS, SIP Alertness
Intellectual scales, and ratings of daily complaints of memory or concentration did not
differ between nonseverely fatigued breast cancer patients and healthy controls (Servaes
15

et al., 2002). However, it would be expected that cancer patients would have greater
cognitive complaints and the lack of group differences does not provide support for the
three measures. The CIS, SIP Alertness Intellectual scales, and ratings of daily
complaints of memory or concentration did not detect significant differences between
patients treated with radiotherapy and chemotherapy, no chemotherapy or radiotherapy,
chemotherapy only, or radiotherapy only (Servaes et al., 2002). This pattern of results
does not support the validity of the CIS, SIP Alertness Intellectual scales, or ratings of
daily complaints of memory or concentration, as group differences would be expected
due to the different treatments.
The checklist of cognitive complaints used in three of the studies (Schagen et al.,
1999, 2002; van Dam et al., 1998) yielded mixed results in detecting group differences.
In one study, high-dose and standard-dose chemotherapy patients reported more
complaints than healthy controls for the three questions assessing concentration, memory
and language, but not the fourth question assessing thinking (van Dam et al., 1998).
Since it would be expected that cancer patients would have more cognitive complaints
than healthy controls, results provide support for the validity of three out of the four
questions. Breast cancer patients treated with conventional chemotherapy also reported
more complaints about concentration and memory than healthy controls (Schagen et al.,
1999), supporting the validity of two out of the four questions. This same sample of
breast cancer patients treated with conventional chemotherapy reported greater
complaints in concentration and memory than the healthy controls two years later
(Schagen et al., 2002), again providing support for the validity of the questions assessing
concentration and memory. However, findings indicated that the question assessing
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thinking did not yield group differences in all three studies. This is contrary to what
would be expected and, therefore, does not support the validity of that question. Findings
indicating that the checklist scores did not differ between the high-dose and the standarddose chemotherapy patients (van Dam et al., 1998) suggest that the checklist was unable
to detect group differences based on treatment type. A two year follow-up assessment
conducted with this sample (Schagen et al., 2002) found no difference in cognitive
complaints assessed by the checklist among high-dose patients, standard-dose patients,
and healthy controls. Group differences would be expected, and the lack of findings does
not support the validity of the checklist.
Mixed support was also found for the validity of the EORTC-CF based on the
detection of group differences. Findings indicating that scores on the EORTC-CF were
higher for patients treated with high-dose chemotherapy than healthy controls (van Dam
et al., 1998) support the validity of the EORTC-CF. The EORTC-CF also detected group
differences between breast cancer patients treated with conventional chemotherapy and
healthy controls at an initial assessment (Schagen et al., 1999) and, again, two years later
(Schagen et al., 2002). The ability of the EORTC-CF to detect expected group
differences between cancer patients and healthy controls supports the validity of the
measure. However, the EORTC-CF did not detect a difference between patients treated
with high-dose chemotherapy and patients treated with low-dose chemotherapy (van Dam
et al., 1998). It would be expected that patients treated with high-dose chemotherapy
would have more cognitive complaints than patients treated with low-dose chemotherapy.
Assessments conducted two years later with the same samples of high-dose
chemotherapy patients, low-dose chemotherapy patients, and healthy controls found no
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group differences in EORTC-CF scores (Schagen et al., 2002). The lack of group
differences at this assessment does not support the validity of the EORTC-CF.
Mixed support was also obtained for other aspects of validity. Five of the eight
studies used multiple measures to assess cognitive complaints. Evidence of concurrent
validity was found in three studies (Schagen et al., 1999, 2002; van Dam et al., 1998) in
which the EORTC-CF was shown to be significantly correlated with a checklist of
cognitive complaints.
Three studies demonstrated convergent validity for the EORTC-CF with anxiety
and depression (Cull et al., 1996; Schagen et al., 1999; van Dam et al., 1998) and three
studies demonstrated convergent validity for the EORTC-CF with fatigue (Cull et al.,
1996; Harder et al., 2002; Servaes et al., 2002). Convergent validity for the EORTC-CF
with health related quality of life was not supported in one study (Cull et al., 1996)
All eight of these studies compared cognitive complaints to cognitive
performance. Six studies (Ahles et al., 2002; Cull et al., 1996; Schagen et al., 1999,
2002; Servaes et al., 2002; van Dam et al., 1998) found no significant relation between
cognitive complaints and cognitive performance. One study (Klein et al., 2002) found
scores for the MOS Cognitive Functioning Scale to be moderately correlated with
neuropsychological measures assessing memory, attention, psychomotor speed, and
graphomotor speed. Another study (Harder et al., 2002) reported a significant correlation
between the EORTC-CF and a composite score for neuropsychological measures.
Taken together, these results yield mixed support for the validity of measures
currently used to assess cognitive complaints in cancer patients. The general lack of
correspondence between measures of cognitive complaints and measures of cognitive
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performance is particularly notable. One reason may be that cognitive complaints and
neuropsychological functioning have been examined as continuous variables. Their
relationship may only be apparent if contrasting groups are used and the relationship of
cognitive complaints to impaired versus non-impaired subjects on neuropsychological
functioning is examined.
The Functional Assessment of Cancer Therapy Cognitive Scale
The FACT-Cog is a measure of cognitive complaints that was recently developed
by Wagner and colleagues (2002). This instrument was created by first obtaining
qualitative data from oncology providers and patients on the perceived impact of
chemotherapy on cognitive functioning and associated impairments in quality of life.
Next, individual interviews were conducted with oncologists, oncology nurses, and
cancer patients. Cancer patients also participated in focus groups. The most commonly
described deficits were memory loss and forgetfulness, impaired concentration, wordfinding difficulties, fatigue, and frustration with these deficits. The oncologists and
nurses reported that these deficits impair patients’ ability to comprehend medical
instructions and adhere to medication regimens. The patients reported that these deficits
interfere in social and work functioning (Wagner et al., 2002).
Based on these findings, 51 items were created to assess a cognitive domain, an
impact on functioning domain, and an impact on quality of life domain. The cognitive
domain consists of subscales assessing mental acuity, concentration, verbal and
nonverbal memory, and verbal fluency. The impact on functioning domain consists of
subscales assessing functional interference due to deficits, others observation of these
deficits, and change from previous functioning. The items in the cognitive domains and
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impact on functioning domains are rated on a 5-point scale (0=Never, 1=About once a
week, 2=Two to three times a week, 3=Nearly every day, 4=Several times a day) of how
often each statement had occurred during the past seven days. The eight items assessing
impact on quality of life are administered twice. The first time the respondents are asked
to rate the items on the 5-point frequency scale described above and the second time the
respondents are asked to rate the items on a 5-point severity scale (0=Not at all, 1=A little
bit, 2=Somewhat, 3=Quite a bit, 4=Very much). To minimize the impact of distress
unrelated to cognitive abilities on responses, the FACT-Cog is primarily composed of
behaviorally based items. The scale was evaluated to be between a fifth and sixth grade
reading level.
Aims
The previously discussed literature demonstrates the lack of reliable and valid
measures currently available to assess cognitive complaints. The most commonly used
measure of cognitive complaints, the EORTC-CF, is of unknown reliability and has
yielded mixed evidence of validity. This state of affairs supports the development of a
new measure, such as the FACT-Cog. The literature has also demonstrated that a
significant portion of BMT patients report cognitive complaints following treatment
(Andrykowski et al., 1989, 1990; Harder et al., 2002; Hjermstad et al., 1999; Schagen et
al., 2002; van Dam et al., 1998). Patients undergoing a BMT receive high-dose
chemotherapy, radiotherapy, or both to deliberately compromise the patient’s immune
system. The immune system is subsequently restored though induction of blood or
marrow products obtained from the same person (autologous transplantation) or from a
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donor (allogeneic transplantation). These characteristics suggest that BMT patients are
an important and appropriate sample for the current study.
The goal of the current study was to examine the psychometric properties of the
FACT-Cog, a newly developed instrument designed to measure perceived cognitive
deficits in people with cancer. The first step was to determine internal consistency. To
evaluate concurrent validity, scores on the FACT-Cog were compared to scores on an
established subjective measure of cognitive deficits, the EORTC-CF. To evaluate
convergent validity, scores on the FACT-Cog were compared to scores on established
self-report measures of depression (Center for Epidemiological Studies Depression Scale
[CES-D]; Radloff, 1977), anxiety (State Version of the State Trait Anxiety Inventory
[STAI-S]; Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983), and fatigue (Fatigue
Symptom Inventory [FSI]; Hann et al., 1998). Also to evaluate convergent validity,
scores on the FACT-Cog were compared to scores on an established measure of healthrelated quality of life (Medical Outcome Study Short From [SF-36]; Ware, Snow,
Kosinski, & Gandek, 1993). To evaluate divergent validity, scores on the FACT-Cog
were compared to scores on an established self-report measure of
extroversion/introversion (NEO Five Factor Inventory Extroversion subscale [NEO-FFI];
Costa & McCrae, 1992a). Finally, to evaluate criterion validity, scores on the FACT-Cog
were compared to scores derived from standardized neuropsychological measures.
Hypotheses
1. There will be a positive relationship between perceived cognitive deficits as
measured by the FACT-Cog and scores on another established subjective measure
of cognitive complaints.
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It is predicted that the total score on the FACT-Cog will be positively
correlated with the total score on the EORTC-CF.
2. There will be a positive relationship between perceived cognitive deficits as
measured by the FACT-Cog and depression.
It is predicted that the total score on the FACT-Cog will be positively
correlated with the total score on the CES-D.
3. There will be a positive relationship between perceived cognitive deficits as
measured by the FACT-Cog and anxiety.
It is predicted that the total score on the FACT-Cog will be positively
correlated with the total score on the STAI-S.
4. There will be a positive relationship between perceived cognitive deficits as
measured by the FACT-Cog and fatigue.
It is predicted that the total score on the FACT-Cog will be positively
correlated with the total score on the FSI Fatigue Disruptiveness Scale.
5. There will be a positive relationship between perceived cognitive deficits as
measured by the FACT-Cog and health-related quality of life.
It is predicted that the total score on the FACT-Cog will be negatively
correlated with the physical component and mental component summary
scales of the SF-36.
6. There will be no relationship between perceived cognitive deficits as measured by
the FACT-Cog and extroversion-introversion.
It is predicted that the total score on the FACT-Cog will not be correlated with
the total score on the NEO-FFI Extroversion scale.
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7a. There will be a negative relationship between perceived cognitive deficits as
measured by the FACT-Cog and standardized neuropsychological measures.
It is predicted that the total score on the FACT-Cog will be negatively
correlated with the total neuropsychological performance score. If this
prediction is supported, exploratory analyses will be conducted to examine
relationships between individual subscales of the FACT-Cog and individual
cognitive domains from the neuropsychological measures.
7b. Cognitive deficits, as measured by the FACT-Cog, will be greater in patients
classified as impaired on neuropsychological performance than in patients
classified as non-impaired on neuropsychological performance.
It is predicted that the total score on the FACT-Cog will be significantly
higher for impaired patients than non-impaired patients. If this prediction is
supported, exploratory analyses will be conducted to examine group
differences for individual subscales of the FACT-Cog.
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Method
Participants
Participants were men and women currently enrolled in a study titled “Cognitive
Function in Patients Undergoing Blood and Marrow Transplantation” at Moffitt Cancer
Center. Eligibility criteria for the aforementioned study were: 1) age between 18 and 75
years; 2) completion of at least 8 years of formal education; 3) the ability to speak and
read standard English; and 4) acceptance into the Moffitt BMT program. Additional
criteria for the current study were that participants in the aforementioned study were
returning to Moffitt to receive neuropsychological testing at either a 6-month or 12month follow-up assessment.
Procedure
Patients who are identified as BMT candidates are routinely scheduled for a
psychosocial evaluation comprised of a clinical interview with a social worker and a brief
evaluation with a psychologist to identify psychological problems and assess quality of
life. From this standard pre-BMT psychosocial evaluation, patients were recruited for the
aforementioned BMT study and randomly assigned to one of three neuropsychological
testing groups. All participants completed psychosocial measures pre-BMT, 6-months
post-BMT, and 12-months post-BMT. Sixty percent of the participants (Group 1) were
assessed with the neuropsychological battery pre-BMT, 6-months post-BMT, and 12months post-BMT. Of the remaining 40 percent of participants, 20 percent received the
neuropsychological battery 6-months post-BMT and 12-months post-BMT (Group 2),
and 20 percent received the neuropsychological battery only at 12-months post-BMT
(Group 3). For the current study, data on estimated intellectual ability and extroversion
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measured for all participants at the pre-BMT assessment were used. The remaining
psychosocial measures and neuropsychological tests were assessed once, at either 6months post-BMT or 12-months post-BMT according to the testing schedule listed
above. A trained research assistant administered the neuropsychological battery. The
psychosocial questionnaires were given to the participant to complete while at Moffitt or
to be taken home and mailed back at the participant’s convenience using a postage paid
envelope that was provided. For their participation in the aforementioned BMT study,
participants were paid 25 dollars upon completion of each of the post-BMT assessments,
regardless of the group to which they were assigned.
Measures
Demographic, Disease, and Treatment Measures
Demographic information was obtained through a background interview.
Variables assessed include: date of birth, handedness, race, marital status, income, and
education. Electronic medical charts were reviewed to obtain information on cancer type,
type of transplant, date of diagnosis, date of admittance, date of transplant, and date of
discharge.
Psychosocial Measures
Perceived Cognitive Functioning. Two instruments were used to assess perceived
cognitive functioning: the Functional Assessment of Cancer Therapy Cognitive Scale and
the EORTC QLQ-C30 Cognitive Functioning Scale. The Functional Assessment of
Cancer Therapy Cognitive Scale (FACT-Cog; Wagner et al., 2002) is a 51-item measure
designed to assess subjective perception of cognitive deficits in cancer patients. Items
were written based on the most commonly identified themes obtained from focus groups
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or individual interviews with oncologists, oncology nurses, and oncology patients. Item
formatting is based on the Functional Assessment of Chronic Illness Therapy (FACIT)
measurement system. The FACT-Cog yields four summary scores: 1) a cognitive
domain score, consisting of mental acuity, concentration, verbal and nonverbal memory,
and verbal fluency subscale scores; 2) an impact on functioning domain score, consisting
of functional interferences, other people noticed deficits, and change from previous
functioning subscale scores; 3) an impact on quality of life domain score; and 4) a total
score. Participants respond on a five-point Likert scale (0=Never to 4=Several times a
day) how often each statement had occurred in the past seven days. The eight items
assessing impact on quality of life are administered a second time where patients respond
on a five-point Likert scale (0=Not at all to 4=Very much) the frequency to which they
have experienced each item. The psychometric properties of this scale are currently
being established. The EORTC QLQ-C30 Cognitive Functioning Scale (EORTC-CF;
Aaronson et al., 1993), consists of two items that measure subjective cognitive
functioning. Participants respond on a four-point Likert scale the extent to which they
have experienced each cognitive complaint in the past week (1=Not at all to 4=Very
much). The EORTC QLQ-C30 Cognitive Functioning Scale has demonstrated validity
with a sample of bone marrow transplant patients, with scores being correlated with total
neuropsychological impairment (r = -.55, p<.001; Harder et al., 2002).
Depression. The Center for Epidemiological Studies – Depression (CES-D;
Radloff, 1977) is a 20-item measure of depressive symptomotology. The items were
selected from a pool of items taken from previously validated depression scales, from the
literature, and from factor analytic studies. Respondents indicate on a four-point rating
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scale (0= rarely or none of the time, 3= most or all of the time) the extent to which they
experienced each depressive symptom during the past week. The CES-D has good
internal consistency with alphas of .85 for the general population and .90 for a psychiatric
population (Radloff, 1977). The validity of the CES-D has been demonstrated with a
wide range of populations, including cancer patients (Beeber, Shea, & McCorkle, 1998;
Hann, Winter, & Jacobsen, 1999).
Anxiety. The State form of the State-Trait Anxiety Inventory (STAI-S;
Spielberger et al., 1983) is a 20-item inventory that measures the level of current anxiety.
Participants respond on a four-point Likert scale (1=Not at all to 4=Very much so) the
extent to which they endorse each item. The internal consistency of the instrument
ranges from .86 to .95 across male and female samples (Spielberger et al., 1983). The
STAI-S has validity correlations of .80 with other established anxiety measures
(Spielberger et al., 1983).
Fatigue. The Fatigue Symptom Inventory (FSI; Hann et al., 1998) is a 14-item
inventory designed to assess the frequency and severity of fatigue as well as its perceived
disruptiveness. Frequency is measured as the number of days in the past week (0-7)
respondents felt fatigued as well as on average, the extent they felt fatigued each day
(0=None to 10=Entire day). Severity is measured on a separate 11-point scale (0=Not at
all fatigued to 10=As fatigued as I could be) that assess most, least, and average fatigue
during the past week as well as current fatigue. Perceived disruptiveness is measured on
a separate 11-point scale (0=No interference to 10=Extreme interference) that assess the
degree to which fatigue in the past week was judged to interfere with general level of
activity, ability to bathe and dress, normal work activity, ability to concentrate, relations
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with others, enjoyment of life, and mood. The interference ratings can also be summed to
obtain a total disruptiveness score. Previous research has demonstrated the reliability and
validity of the FSI with individuals diagnosed with cancer (Hann et al., 1998).
Health-Related Quality of Life. The Medical Outcome SF-36 Health Survey (SF36; Ware et al., 1993) is a 36-item measure of various aspects of perceived health,
functioning, and quality of life. It contains eight subscales that measure the extent to
which health status impacts each of the following areas; 1) physical functioning; 2) role
functioning-physical; 3) bodily pain; 4) general health; 5) vitality; 6) social functioning;
7) role functioning- emotional; and 8) mental health. The SF-36 also yields two
summary scores that measure global physical functioning (physical component summary
scale) and global mental health functioning (mental component summary scale). The
items use Likert-type scales, some with five or six points and others with two or three
points. Correlations ranging from .52 to .78 have been reported between the SF-36
subscales and other QOL measures (Ware & Sherbourne, 1992; McHorney, Ware, &
Raczek, 1993). Test-retest reliability coefficients range from .68-.93 for the various
subscales. The SF-36 has been found to have acceptable reliability and validity when
administered to healthy and chronically ill individuals (Ware et al., 1993).
Extroversion and Neuroticism. The Neuroticism, Extroversion, and Openness –
Five-Factor Inventory (NEO-FFI; Costa & McCrae, 1992a) is a 60-item personality
measure based on the five-factor model of personality. The five factors assessed are
Neuroticism, Extroversion, Openness, Agreeableness, and Conscientiousness. Responses
are made on a five-point scale ranging from strongly disagree to strongly agree. Factor
analyses have provided support for these factors with coefficient alphas for the five
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domain scores ranging from .86 to .95 and test-retest coefficients ranging from .63 to .81
(Costa & McCrae, 1992b, c). For the purpose of this study, only the Extroversion and
Neuroticism scales were examined.
Neuropsychological Measures
Estimated Intellectual Functioning. The National Adult Reading Test (NART;
Nelson, 1982) contains 50 irregular words that cannot be easily phonetically decoded.
Inter-rater reliability is high ranging from .96 to .98 and test-retest reliability is high at
.98 (Crawford, Parker, Stewart, Besson, & De Lacey, 1989). Previous studies have
shown that performance on the NART is highly correlated with the general factor of
intelligence ‘g’ from the Wechsler scales (Crawford et al., 1989).
Attention. The Conners’ Continuous Performance Test (CPT-II; Conners, 2000)
is a measure of sustained attention administered on the computer. Participants monitor a
random series of single numbers or letters, which are presented continuously. They are
asked to indicate that they have detected a target event by pressing the space bar while
avoiding responding to distracting stimuli. The CPT-II yields three scores: impulsivity,
vigilance, and inattention. Test-retest reliability is high at .92 and validity of the CPT-II
has been demonstrated with neurological, clinical, and nonclinical populations (Conners,
2000).
Memory. Memory was assessed using three measures: the California Verbal
Learning Test; the Logical Memory subtest from the Wechsler Memory Scale-III (WMSIII); and the Visual Reproduction subtest from the WMS-III. The California Verbal
Learning Test (CVLT; Delis, Kramer, Kaplan, & Ober, 1987) assesses verbal learning
and memory. The test consists of five presentations and recall of a 16-item list of words
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belonging to four semantic categories. An interference list of 16-items containing eight
words from two shared semantic categories is presented, followed by free recall and a
category-cued recall of the original list. Retention is tested 20 minutes after learning by
free recall, category-cued recall, and recognition. Split-half reliability and coefficients
alpha are in the moderate to high range (Delis et al., 1987). The CVLT correlates well
with other measures of memory and learning (Spreen & Strauss, 1998). The Logical
Memory subtest from the WMS-III (Wechsler, 1997) assesses memory for prose. Two
short stories are read aloud to the participant followed by immediate and delayed recalls
and a recognition paradigm. Internal consistency assessed by split-half reliability ranges
between .67 and .80 and the inter-scorer reliability coefficient is .99 (Wechsler, 1997).
The Visual Reproduction subtest from the WMS-III (Wechsler, 1997) assesses nonverbal
memory for designs. Five novel designs are each presented individually for 10 seconds,
and the participant is asked to reproduce the design from memory. After a 30 minutes,
delayed recall and recognition paradigm are performed. Reliability coefficients for
immediate recall and delayed recall are .59 and .46. Inter-scorer reliability is reported at
.97 (Wechsler, 1997).
Executive Functioning. Executive functioning was assessed using four
instruments: 1) Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol, 2)
Trail Making Test, 3) Controlled Oral Word Association, and 4) Stroop
Neuropsychological Screening Test. The WAIS-R Digit Symbol (Wechsler, 1981) is a
test of sustained attention, psychomotor speed, and motor persistence. It requires
participants to match numbers with a geometric mark according to a designated code. It
is consistently noted to be the most sensitive Wechsler subtest to brain dysfunction
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(Lezak, 1995). Test-retest reliability ranges from .82-.86 for adults (Wechsler, 1997). It
has been shown to be a sensitive indicator of cognitive changes in BMT candidates
(Ahles, Tope, Furstenberg, Hann, & Mills, 1996). The Trail Making Test (TMT; Reitan
& Wolfson, 1993) assesses the participant’s ability to follow a simple number sequence
(Trails A) and their ability to follow a complex sequence of alternating numbers and
letters (Trails B). Extensive reliability data are presented in Spreen and Strauss (1998),
including reliability coefficients of .69 to .94 for Trail A, and .66 to .86 for Trail B.
Strong validity of the TMT as an indicator of mild to severe cognitive dysfunction has
been reported with Trails B more sensitive to deficits (Reitan, 1958). The TMT has been
shown to be sensitive to BMT treatment effects (Andrykowski et al., 1992). The
Controlled Oral Word Association (COWA) from the Multilingual Aphasia Examination
(Benton & Hamsher, 1989) assesses the speed and ease of word production and is a
measure of executive function (e.g., initiation, perseveration and effortful output).
Participants are asked to generate as many words as possible beginning with a target
letter provided by the examiner over a one-minute trial. There are three trials and
respondents are requested to not use proper nouns or the same words with different
suffixes. Inter-scorer reliability is excellent, and test-retest reliability ranges from .70 to
.88, as reported in Spreen & Strauss (1998) who also report strong concurrent validity.
The COWA has been shown to be a sensitive measure with BMT candidates (Ahles et al.,
1996). The Stroop Neuropsychological Screening Test (Stroop; Trenarry, Crosson,
DeBoe, & Leber, 1989) is a task of effortful attention and speed and is sensitive to subtle
attentional deficits (Lezak, 1995; Spreen & Strauss, 1998). The Stroop consists of two
trials: one in which the subject reads the words printed on a page and one in which the
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subject names the color of the ink that the word is printed in. Test-retest reliability is
high (.90) and validity data indicate that the Stroop can discriminate cognitively impaired
groups from normal groups (Trenarry et al., 1989).
Motor. The Grooved Pegboard (Matthews & Klove, 1964) evaluates speeded
manual dexterity. It requires the participants to place ridged pegs in a 5 X 5 square array
with slots that are at various orientations requiring rotation of the pegs for correct
placement. This level of complexity makes this task sensitive to general psychomotor
slowing caused by medication and disease effects (Lezak, 1995). Fatigue and treatment
with BMT have been shown to negatively impact the time to complete this task
(Andrykowski, 1992).
Data Reduction
In order to avoid Type I statistical errors, the 22 test scores generated from these
measures were grouped into the following four cognitive domains as suggested by Lezak
(1995): Attention (CPT); Memory (CVLT, Logical Memory, Visual Reproduction);
Executive Functioning (Digit Symbol, TMT, COWA, Stroop); and Motor (Grooved
Pegboard). To accomplish this, raw scores were converted into z-scores according to
published normative data (Heaton, 1992; Heaton, Grant, & Matthews, 1991; Spreen and
Strauss, 1998; Wechsler, 1997) and then averaged according to domain. A total
neuropsychological performance index was computed for each subject by deriving the
average z-score from the 22 measures.
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Statistical Analyses
Descriptive statistics (mean and standard deviations) were used to characterize the
demographic, disease, and treatment characteristics of the sample. Cronbach alpha
coefficients were calculated to evaluate internal consistency of the total score and domain
scores of the FACT-Cog. Prior to conducting the main analyses, exploratory analyses
were conducted to examine the relationship of demographic and clinical variables to the
FACT-Cog total score and domain scores.
To test the first hypothesis, a correlational analysis was performed to compare the
total score of the FACT-Cog with the total score on the EORTC-CF. A correlational
analysis was also performed to compare the FACT-Cog domain scores with the total
score on the EORTC-CF. To test the second hypothesis, a correlational analysis was
performed to compare the total score of the FACT-Cog with the total score on the CESD. A correlational analysis was also performed to compare the FACT-Cog domain
scores with the total score on the CES-D. To test the third hypothesis, a correlational
analysis was performed to compare the total score of the FACT-Cog with the total score
on the STAI-S. A correlational analysis was also performed to compare the FACT-Cog
domain scores with the total score on the STAI-S. To test the fourth hypothesis, a
correlational analysis was performed to compare the total score of the FACT-Cog with
the total score on the FSI Fatigue Disruptiveness Scale. A correlational analysis was also
performed to compare the FACT-Cog domain scores with the total score on the FSI
Fatigue Disruptiveness Scale. To test the fifth hypothesis, a correlational analysis was
performed to compare the total score of the FACT-Cog with the physical component and
mental component summary scales of the SF-36. A correlational analysis was also
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performed to compare the FACT-Cog domain scores with the physical and mental
component summary scales of the SF-36. Additional correlational analyses were
performed to compare the FACT-Cog total score and domain scores with the total score
on the NEO-FFI Neuroticism scale. To test the sixth hypothesis, a correlational analysis
was performed to compare the total score of the FACT-Cog with the total score on the
NEO-FFI Extroversion scale. A correlational analysis was also performed to compare
the FACT-Cog domain scores with the total score on the NEO-FFI Extroversion scale.
To test the first part of the seventh hypothesis, a correlational analysis was performed to
compare the total score of the FACT-Cog with the total neuropsychological performance
score. A correlational analysis was also performed to compare the FACT-Cog domain
scores with the total neuropsychological performance score. Correlational analyses were
performed to compare the FACT-Cog total score and domain scores to the
neuropsychological domain scores and individual test scores. To test the second part of
the seventh hypothesis, a correlational analysis was performed to compare the total score
of the FACT-Cog for the patients classified as impaired and non-impaired on total
neuropsychological performance. A correlational analysis was also performed to
compare the FACT-Cog domain scores for patients classified as impaired and nonimpaired on total neuropsychological performance. Classification as impaired on total
neuropsychological performance was defined as obtaining a z-score at or below –1.5 on
three or more neuropsychological tests, similar to the definition used by Schagen et al.
(2002). Correlational analyses were performed to compare the FACT-Cog total score
and domain scores for patients classified as impaired on neuropsychological domain
scores and individual test scores. Performance on individual domains was classified as
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impaired if the mean z-score for the domain was at or below –1.5 or at least 50 percent of
the z-scores comprising that domain were at or below –1.5 (Lezak, 1995). Performance
on individual test scores were classified as impaired if the z-score was at or below –1.5.
In addition, multivariate analyses were conducted. A multiple regression analysis
was conducted for the FACT-Cog total score. Demographic variables that were
significantly correlated with the FACT-Cog total score were entered into the equation
first. Psychosocial variables that were significantly correlated with the FACT-Cog total
score were then entered into the equation using a forward selection technique with a p <
.05 selection criterion. Multiple regression analyses were also conducted for each FACTCog domain score using the same procedure. A uniqueness index was calculated for each
variable in the regression analyses by subtracting the variance accounted for by all the
variables without the target variable from the total variance accounted for by all of the
variables.
In order to determine the necessary sample size for correctional analyses, a power
analyses was conducted. With 81 participants (p < .05, two-tailed), there was power of
.80 to detect a correlational coefficient of .30 (medium effect size; Cohen, 1988).
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Results
A total of eighty-two participants completed the six-month or twelve-month
follow-up assessment. Participants ranged in age from 23 to 72 years old (M = 52.91; SD
= 12.03) with a similar number of males (N = 42) and females (N = 40). Education
ranged from 8 to 23 years (M = 13.76; SD = 2.30) and estimated IQ (NART scores)
ranged from 80 to 124 (M = 98.5; SD = 15.3). A majority of these individuals were
Caucasian (85%), married (79%), had received autologous stem cell transplantation
(85.4%), and had been diagnosed with multiple myeloma (72%). Approximately 49% of
participants reported an annual household income of at least $40,000, 28% were working
full-time, and 21% reported not working due to disability. See Table 1 for complete
demographic information and Table 2 for complete clinical characteristics.
Relationship of FACT-Cog to Demographic Characteristics
Exploratory analyses were conducted to determine the relationship between
demographic variables and the FACT-Cog total score (see Table 3). Gender was
significantly associated with the total score, indicating that women had greater cognitive
complaints (p < .01). Age, estimated IQ, years of education, race, marital status,
diagnosis, type of transplant, and time since transplant (6 month or 12 month follow-up)
were not significantly correlated with the total score (p values > .05). Internal
consistency of the FACT-Cog total score was high (α = .983), demonstrating the
reliability of the measure. Exploratory analyses were also conducted with each of the
FACT-Cog domain scores. Gender was significantly associated with the cognitive
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domain, interference of functioning domain, and quality of life domain (p values < .05).
Estimated IQ was significantly correlated with the quality of life domain (p < .05). Age,
years of education, race, marital status, diagnosis, type of transplant, and time since
transplant were not significantly correlated with any of the domain scores (p values >
.05). Internal consistency was high for the cognitive domain (α = .962), the interference
of functioning domain (α = .959), and the quality of life domain (α = .957). The FACTCog domain scores were highly correlated with each other. The highest correlation was
between the cognitive domain and the interference of functioning domain (r = .92, p <
.0001), followed by the interference of functioning domain and quality of life domain (r =
.84, p < .0001). The lowest correlation was between the cognitive domain and the quality
of life domain (r = .78, p < .0001).
Relationship of FACT-Cog to Psychosocial Variables
As hypothesized, the FACT-Cog total score was significantly correlated with the
EORTC-CF supporting the concurrent validity of the measure (r = .66, p <.0001). The
FACT-Cog cognitive, interference of functioning, and quality of life domain scores were
also significantly correlated with the EORTC-CF. (r = .65, .68, and .57 respectively, p
values < .0001).
To test the convergent validity of the FACT-Cog, hypothesized relationships
between the total score and psychosocial variables were tested. As expected (see Table
4), the FACT-Cog total score was significantly correlated with measures of depression,
fatigue, anxiety, mental well-being, and physical well-being (p values < .01). All three
domain scores were also significantly correlated with measures of depression, fatigue,
anxiety, mental well-being and physical well-being (p values < .05).
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To assess divergent validity, the correlations of the FACT-Cog with extroversion,
as measured by the NEO Personality Inventory, were examined. Consistent with
expectations, the FACT-Cog total score was not significantly correlated with
extroversion (p > .05). The cognitive domain score and the quality of life domain score
were also not significantly correlated with extroversion (p > .05), however, the
interference of functioning domain score was significantly correlated with extroversion (p
< .05).
The relationship of neuroticism with the FACT-Cog was also examined. The
FACT-Cog total score, cognitive domain score and interference of functioning domain
score were significantly correlated with neuroticism (p < .05). The quality of life domain
score was not significantly correlated with neuroticism (p >.05).
An exploratory regression analysis was conducted to determine the relative
contribution of psychosocial variables to the total variance of the FACT-Cog total score
(see Table 5). To control for the contribution of gender, which was significantly related
to the FACT-Cog total score (p < .05), it was entered first. After controlling for gender,
the psychosocial variables that were significantly correlated with the total score in
univariate analyses were entered into the equation using the forward selection technique
with a p < .05 selection criterion. Gender accounted for 9% of the variance in the FACTCog. Fatigue entered the model on the second step and accounted for 23% of the
remaining variance (p < .0001). The final variable to enter the model was mental wellbeing, which accounted for 5% of the remaining variance (p < .05). Together, these
variables accounted for 37% of the total variance in the FACT-Cog. Physical well-being,
anxiety, neuroticism and depression did not account for significant additional variance.
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Regression analyses were also conducted for each FACT-Cog domain score using
the previously described method. For the cognitive domain (see Table 6), gender was
entered into the equation first and accounted for 9% of the variance. Mental well-being
entered into the equation next accounting for 18% of the remaining variance (p < .0001).
Together, these variables accounted for 27% of the total variance in the FACT-Cog
cognitive domain. Fatigue, neuroticism, anxiety, depression, and physical well-being did
not account for significant additional variance. For the interference of functioning
domain (see Table 7), gender was controlled for and accounted for 10% of the variance.
Mental well-being entered into the equation next accounting for 22% of the remaining
variance (p < .0001). Together, these variables account for 32% of the total variance in
the FACT-Cog interference of functioning domain. Fatigue, extroversion, anxiety,
depression, and physical well-being did not account for significant additional variance.
For the quality of life domain (see Table 8), gender and IQ were entered into the equation
first and accounted for 10% of the variance. Fatigue entered into the equation next
accounting for 26% of the remaining variance (p < .0001). Together, these variables
account for 36% of the total variance in the FACT-Cog quality of life domain. Mental
well-being, anxiety, depression, and physical well-being did not account for significant
additional variance.
A uniqueness index was calculated to determine the variance accounted for that is
unique to each variable. For the total score (see Table 5), gender contributed the largest
amount of unique variance (4%) followed by fatigue (3%) and mental well-being (2%).
Neuroticism and anxiety each accounted for 1% of unique variance. Depression and
physical well-being each accounted for less than 1% of unique variance in the FACT-Cog
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total score. For the cognitive domain score (see Table 6), gender and neuroticism each
contributed the largest amount of unique variance (4%) followed by anxiety (2%).
Mental well-being, fatigue, and depression each accounted for 1% of unique variance,
and physical well-being accounted for less than 1% of unique variance. For the
interference of functioning domain (see Table 7), gender contributed the largest amount
of unique variance (5%) followed by mental well-being (4%). Fatigue and extroversion
each contributed 2% of unique variance and anxiety contributed 1% of unique variance.
Physical well-being and depression each contributed less than 1% of unique variance.
For the quality of life domain (see Table 8), fatigue contributed the most unique variance
(3%). Gender and mental well-being each contributed 1% of unique variance. Estimated
IQ, depression, physical well-being, and anxiety each accounted for less than 1% of
unique variance.
Relationship of FACT-Cog to Neuropsychological Variables
Contrary to expectations, the FACT-Cog total and domain scores were not
significantly related to the total neuropsychological performance score (see Table 9).
The lack of significant findings may be a result of a decrease in sensitivity due to the
averaging of multiple tests assessing different aspects of cognitive functioning.
Therefore, exploratory analyses were conducted to correlate the FACT-Cog with the
neuropsychological domain scores and individual test scores (see Tables 9 and 10). The
FACT-Cog total and domain scores were not significantly correlated with the four
domain scores (memory, executive functioning, motor, and attention). With regards to
individual test scores, a significant correlation was found between the quality of life
domain score and the vigilance subscale of the CPT-II (p < .05), with higher cognitive
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complaints being related to lower vigilance. All other correlations between the FACTCog total and domain scores and the individual neuropsychological test scores were nonsignificant.
To determine if patients with greater cognitive complaints had greater impaired
performance on neuropsychological tests (see Table 11), neuropsychological test scores
were dichotomized into impaired or non-impaired based on the previously described
criterion. The FACT-Cog total and domain scores were not significantly correlated with
impairment classification based on the total neuropsychological performance score. As
previously mentioned, these results may be a related to of loss of sensitivity, therefore
exploratory analyses were conducted. The FACT-Cog total and domain scores were not
significantly correlated with the four neuropsychological domain scores (see Table 11).
When individual neuropsychological test scores were examined, significant correlations
did arise with the CPT-II subscales with higher cognitive complaints associated with
impaired performance (see Table 12). Impaired performance on the CPT-II impulsivity
subscale was significantly correlated with the FACT-Cog total score and the three
domain scores (p < .05). The FACT-Cog total score and quality of life domain score
were also significantly correlated with the CPT-II vigilance subscale (p < .05). The
direction of these relationships is for impaired performance to be associated with more
cognitive complaints. In addition, the FACT-Cog cognitive domain score was
significantly correlated with the short delay cued recall score and the long delay free
recall score of the CVLT (p < .05). The direction of this relationship is for impaired
performance to be associated with fewer cognitive complaints.
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To better understand the results, the rates of impairment were examined. The
Grooved Pegboard (dominant and nondominant hand) had the highest rates of
impairment of individual tests (26.8% and 31.7% respectively). The COWA had the next
highest rate at 13.4%. For all of the other individual tests, the percentage of scores
classified as impaired ranged from 8.5% to 1.2%. Rate of impairment in the domain
scores were also low, except for the motor domain which had the highest impairment rate
at 37.8%. The memory domain and the executive functioning domain each had an
impairment rate of 3.7%. The attention domain had the lowest rate of impairment at
2.4%.
Relationship of EORTC-CF to Demographic Variables
Parallel analyses were performed to study the relationship of the EORTC-CF and
the demographic, psychosocial, and neuropsychological variables. The EORTC-CF was
significantly related to gender (p = .04), with women having greater cognitive
complaints, type of transplant (p = .01), with patients who received an autologous
transplantation having greater cognitive complaints than patients who received an
allogeneic transplantation, and race (p = .05), with Caucasians having more cognitive
complaints than non-Caucasians (see Table 3). Age, estimated IQ, years of education,
marital status, diagnosis, and time since transplant were not significantly correlated with
the EORTC-CF (p values > .05). The EORTC-CF had strong internal consistency (α =
.77).
Relationship of the EORTC-CF to Psychosocial Variables
The EORTC-CF was significantly correlated with depression, fatigue, anxiety,
mental well-being, and physical well-being (p values < .001; see Table 3). The EORTC42

CF was also significantly correlated with extroversion (p < .001), but not with
neuroticism (p >.05; see Table 3).
A regression analysis was conducted with the EORTC-CF to examine which
psychosocial variables accounted for a significant amount of the variance (see Table 13).
Type of transplant, gender, and race were significantly correlated with the EORTC-CF in
univariate analyses, therefore, these three variables were controlled for by being entered
into the equation first. Next, the psychosocial factors were entered using a forward
selection technique with a p < .05 selection criterion. Type of transplant, gender, and
race accounted for 16% of the variance in the EORTC-CF. Mental well-being entered
the model in the second step accounting for 20% of the remaining variance (p < .0001).
Together, these variables account for 37% of the total variance in the EORTC-CF.
Physical well-being, extroversion, fatigue, anxiety, and depression did not account for
significant additional variance.
A uniqueness index was calculated to determine the amount of unique variance
each psychosocial variable contributed (see Table 13). Type of transplant accounted for
the most unique variance (6%), followed by extroversion (3%). Gender, race, and mental
well-being each accounted for 2% of unique variance in the EORTC-CF. Fatigue
accounted for 1% of unique variance and physical well-being, anxiety, and depression
each accounted for less than 1% of unique variance.
Relationship of the EORTC-CF to Neuropsychological Variables
The EORTC-CF was not significantly correlated with the total
neuropsychological performance score (see Table 9). As previously stated, the lack of
significant findings may be a result of a decrease in sensitivity due to the averaging of
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multiple tests. Exploratory analyses found that the EORTC-CF was not significantly
correlated with the four neuropsychological domain scores (see Table 9). With regards to
individual test scores (see Table 10), the EORTC-CF was significantly correlated with
the impulsivity subscale of the CPT-II (p < .05). The direction of this relationship is for
impaired performance to be associated with more cognitive complaints.
The EORTC-CF was correlated with neuropsychological tests scores that were
classified as impaired or non-impaired, based on previously described criterion, to
determine if patients with greater complaints had greater impaired performance (see
Table 11). The correlations between the EORTC-CF and impairment classification of the
total score were nonsignificant. This finding may be a result of lack of sensitivity,
therefore exploratory analyses were conducted. No significant correlations were found
between the EORTC-CF and impairment of any domain scores (see Table 11). When
looking at individual test scores (see Table 12), the EORTC-CF was significantly
positively correlated with impairment classification for the delayed visual reproduction
score (p < .05), the inattention subscale of the CPT-II (p < .05), and the impulsivity
subscale of the CPT-II (p < .01). The direction of these relationships is for impaired
performance to be associated with more cognitive complaints.
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Discussion
The aim of the current study was to examine the psychometric properties of the
FACT-Cog, a recently developed instrument designed to measure perceived cognitive
deficits in people with cancer. The following section will first evaluate the reliability and
validity of the FACT-Cog. Second, additional demographic and multivariate analyses
conducted will be reviewed. Next, the FACT-Cog will be compared with the EORTCCF, an established measure of cognitive complaints. Finally, limitations of this study,
clinical implications, and future directions for research will be discussed.
Reliability
The reliability of the FACT-Cog total score was strong, as evidenced by its high
internal consistency. The FACT-Cog cognitive, interference of functioning, and quality
of life domain scores also demonstrated high internal consistency. Test-retest reliability
was not evaluated and thus remains unknown.
Concurrent Validity
As hypothesized, the FACT-Cog total score was significantly correlated with the
EORTC-CF. This significant relationship with an established measure of cognitive
complaints provides support for the concurrent validity of the FACT-Cog total score.
The concurrent validity of the three FACT-Cog domain scores was also supported by
their significant relationships with the EORTC-CF.
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Convergent Validity
As hypothesized, the FACT-Cog total score was significantly correlated with
measures of depression, fatigue, anxiety, mental well-being, and physical well-being.
These findings provide evidence for the convergent validity of the FACT-Cog. The same
pattern of results was found for the FACT-Cog domain scores. Additional analyses were
conducted to examine the relationship of neuroticism to the FACT-Cog total and domain
scores. Although no a priori hypothesis about this relationship was made, previous
research has found that people with cancer who are high on neuroticism often report
worse psychosocial outcomes (Aarstad, Aarstad, Birkhaug, Bru, & Olofsoon, 2003).
Therefore, it would be expected that patients high on neuroticism would have greater
cognitive complaints. Results for the FACT-Cog total score and cognitive domain and
interference of functioning domain scores supported this expectation. The FACT-Cog
quality of life domain score, however, was not significantly correlated with neuroticism.
These results are consistent with previous research that has found cognitive
complaints to be significantly related to psychosocial factors. More specifically, the
significant relationship between depression and cognitive complaints was found in
research with cancer patients by Cull et al. (1996), Schagen et al. (1999), and van Dam et
al. (1998) using other cognitive complaints measures. The results of this study, regarding
the relationship of fatigue and cognitive complaints, were also consistent with previous
research with cancer patients (Cull et al., 1996; Harder et al., 2002; Servaes et al., 2002).
The significant relationship between anxiety and cognitive complaints in this study is
consistent with the previous cancer research as well (Cull et al., 1996; Schagen et al.,
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1999; Van Dam et al., 1998). Previous research has not looked specifically at
relationship with measures of mental well-being and physical well-being.
Although the FACT-Cog was significantly correlated with measures of depression
and fatigue, the FACT-Cog shared only 25% of its variance with depression and 28% of
its variance with fatigue. This suggests that cognitive complaints is a distinct construct
from depression and fatigue.
Divergent Validity
As hypothesized, the FACT-Cog total score was not correlated with a measure of
extroversion. This finding reflects the expected pattern for divergent validity. There was
mixed support for the divergent validity of the FACT-Cog domain scores. As expected,
the cognitive and quality of life domains were not significantly correlated with
extroversion, however, the interference of functioning domain was significantly
correlated with extroversion.
Previous research has not examined the divergent validity of cognitive complaints
measures. This is the first study to examine the relationship of cognitive complaints to
extroversion to assess divergent validity. Previous research has not found a significant
relationship between extroversion and depression (Van der Zee, Buunk, Sanderman,
Botke, & Van der Bergh, 1999), or between extroversion and quality of life (Aarstad et
al., 2003) in cancer patients.
Criterion Validity
Hypotheses regarding the criterion validity of the FACT-Cog were generally not
supported. Contrary to predictions, the FACT-Cog total and domain scores were not
significantly related to the total and domain scores for the neuropsychological measures.
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Likewise, when the neuropsychological total and domain test scores were dichotomized
as impaired or nonimpaired, no significant relationships were found with the FACT-Cog
scores.
To rule out the possibility that the lack of significant findings may have been
related to a loss of sensitivity due to the averaging of multiple tests assessing different
aspects of cognitive performance, the relationship of the FACT-Cog total and domain
scores to individual neuropsychological test scores was also examined. These analyses
did yield a limited number of significant findings. The FACT-Cog quality of life domain
was significantly correlated with continuous scores on the vigilance subscale of the CPTII. When neuropsychological performance was classified as impaired or nonimpaired,
the impulsivity subscale of the CPT-II was significantly correlated with the FACT-Cog
total score and all three FACT-Cog domain scores. The vigilance subscale was
significantly correlated with the FACT-Cog total score and quality of life domain score.
In all of these instances, poorer performance on the CPT-II was associated with greater
cognitive complaints. The short delay cued recall and the long delay free recall subscales
of the CVLT test in the memory domain were also significantly related to the FACT-Cog
cognitive domain score. In this instance, better performance on the CVLT was associated
with greater cognitive complaints.
Of note, few participants had impaired performance on the neuropsychological
tests. However, the increased number of significant relationships when the scores are
dichotomized suggests that there are subcategories of cognitive performance. Although
no other correlations between the FACT-Cog and neuropsychological test scores were
significant, tests in the memory domain and motor domain had small to medium effect
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sizes for correlational analyses (r = .15 to .19) as suggested by Cohen (Cohen, 1987).
This suggests that there may be a power issue, in that the sample size was too small to
detect significant findings of these more subtle effects.
In general, the lack of significant correlations between cognitive complaints and
cognitive performance found in this study is consistent with the literature on cancer
patients. Ahles et al. (2002) found that correlations between neuropsychological domain
scores and cognitive complaints were nonsignificant. Van Dam et al. (1998) and
Schagen et al. (1999, 2002) also found no significant relationship between cognitive
complaints and neuropsychological total and domain scores. Two studies that examined
the relationship between cognitive complaints and individual neuropsychological test
scores have also reported nonsignificant relationships (Cull et al., 1996; Servaes et al.,
2002). However, Klein et al. (2002) did find significant correlations between cognitive
complaints and individual test scores measuring memory, attention, psychomotor speed,
and graphomotor speed. Only one study reported results generally inconsistent with the
current study’s findings. Harder et al. (2002) reported a significant correlation between
cognitive complaints as measured by the EORTC-CF and a total neuropsychological
impairment performance score. With regards to criterion validity, the FACT-Cog cannot
be considered superior to existing measures of cognitive complaints.
Demographic and Multivariate Analyses
When examining the relationship of the FACT-Cog total and domain scores to
demographic variables, all FACT-Cog scores were significantly correlated with gender,
with women having more cognitive complaints than men. The FACT-Cog quality of life
domain score was also significantly related to estimated IQ, with higher estimated IQ
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associated with greater complaints. The FACT-Cog total and domain scores were not
significantly related to age, years of education, race, marital status, diagnosis, type of
transplant, and time since transplant.
The significant relationship between cognitive complaints and gender has not
been found in previous research with cancer patients. Few studies have reported testing
for gender differences, but ones that did found no significant relationship between
cognitive complaints and gender (Andrykowski et al., 1990; Cull et al., 1996; Hjermstad
et al., 1999). However, women have been found to report higher levels of neuroticism
than men (Goodwin & Gotlib, 2004), and since neuroticism has been associated with
more subjective health complaints in cancer patients (Aarastad et al., 2003), women may
be expected to have more cognitive complaints than men. One study found that cognitive
complaints were related to years of education (Andrykowski et al., 1990), however,
another study found no such relationship (Cull et al., 1996). Consistent with this study,
cognitive complaints were not significantly related to age in two studies (Andrykowski et
al., 1990 & Cull et al., 1996). Cull et al. (1996) also found that cognitive complaints
were not significantly related to estimated IQ, which is consistent with the findings for
the FACT-Cog total score and cognitive and interference of functioning domain scores.
The current study found no significant difference between types of BMT. This finding is
inconsistent with one study that found patients who received autologous BMT had more
complaints that patients who received allogeneic BMT (Hjermstad et al., 1999), but is
consistent with other research that found so significant differences between different
types of treatment groups (Cull et al., 1996; Schagen et al., 2002; Van Dam et al., 1998).
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Regression analyses were conducted, controlling for significant demographic
variables, to determine which psychosocial variables accounted for a significant amount
of the variance in the FACT-Cog total score and domain scores. Only fatigue and
mental-well being accounted for a significant amount of the remaining variance in the
FACT-Cog total score after controlling for gender. For the FACT-Cog cognitive and the
interference of functioning domain scores, only mental well-being accounted for a
significant amount of the remaining variance after controlling for gender. For the FACTCog quality of life domain score, only fatigue accounted for a significant amount of the
remaining variance after controlling for gender and estimated IQ.
Fatigue and mental well-being were the only two psychosocial factors that
contributed a significant amount of additional variance in the FACT-Cog total score and
domain scores. However, the small uniqueness index for all of the variables in the
regression analyses indicates that there was significant overlap in the contributions of
each variable.
FACT-Cog Total Score in Comparison to the EORTC-CF
The FACT-Cog was designed to be a comprehensive measure of cognitive
complaints. Therefore, the psychometric properties of the FACT-Cog total score were
compared to an established measure of cognitive complaints, the EORTC-CF. Both
measures demonstrated adequate internal consistency reliability, however, the FACT-Cog
total score had a slightly higher internal consistency than the EORTC-CF (.98 vs. .77).
The FACT-Cog total score and EORTC-CF provided equally strong evidence for
convergent validity. Both were significantly correlated with measures of depression,
fatigue, anxiety, mental well-being and physical well-being. While the FACT-Cog total
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score demonstrated divergent validity with extroversion, the EORTC-CF was
significantly correlated with extroversion. Therefore the divergent validity of the
EORTC-CF was not supported. An additional analysis to examine the relationship
between the EORTC-CF and neuroticism did not find a significant relationship as would
be expected, and as found with the FACT-Cog total score.
There was minimal support for criterion validity for both measures. Neither the
FACT-Cog total score nor the EORTC-CF was significantly correlated with total
neuropsychological performance or with the neuropsychological domain scores
(continuous or impairment classifications). When the relationship to the individual test
scores as continuous measures was examined, the EORTC-CF yielded similar results to
the FACT-Cog total score, with a significant relationship with one of the CPT-II
subscales. Relationship of the EORTC-CF to individual test scores classified as impaired
or nonimpaired also produced results similar to the FACT-Cog total score, with
significant findings mainly within the attention domain. Similar to the FACT-Cog total
score, other correlations of individual tests with the EORTC-CF, although nonsignificant,
had small to medium effect sizes. Again, this suggests that power may have been an
issue for both measures.
When examining the relationship of the cognitive functioning measures to
demographic and clinical variable, the FACT-Cog total score was significantly correlated
with gender only, while the EORTC-CF was significantly correlated with gender, race,
and type of BMT transplant. There is no a priori reason to think that cognitive
complaints should be related to race or type of BMT transplant. In the absence of an a
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priori reason, the relationship of the EORTC-CF to race and type of transplant is
undesirable.
Although these measures demonstrated similar psychometric properties, the
content of the measures varies greatly. A strength of the EORTC-CF is the brevity of the
measure. However, this brevity also means that the content of the EORTC-CF is very
narrow assessing only memory and attention. In comparison, a weakness of the FACTCog is the length of the measure, but this allows the FACT-Cog to assess broader aspects
of cognitive complaints. Although in this sample the FACT-Cog domain scores had
similar results to the FACT-Cog total score showing no clear advantage of domain
scores, the utility of the FACT-Cog domain scores may yet be identified.
Limitations
Several limitations of the current study should be noted. First, the cross-sectional
design of the study did not allow test-retest reliability to be assessed to demonstrate the
temporal stability of the measure. Second, the cross-sectional design also meant that the
neuropsychological measures and FACT-Cog were only administered once. Therefore,
how changes in cognitive performance may relate to changes in cognitive complaints
could not be assessed. Cognitive complaints may not reflect actual cognitive
performance, rather they may reflect a change from previous functioning. Looking at
discrete cognitive performance in relationship to cognitive complaints may not be an
accurate means of evaluating criterion validity. Third, the sample size may have been too
small to detect significant differences for small to medium effect sizes. Fourth, the
generalizabilty of these results may be limited to patients receiving a BMT. Fifth, the
sample was predominantly Caucasian, married, well-educated, and economically stable
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potentially limiting the generalizabilty of the results to a more socioeconomically diverse
group. A final limitation is that the individual neuropsychological tasks generally did not
require sustained effort. Therefore these tasks may not have been demanding enough to
simulate the types of cognitive complaints assessed by the FACT-Cog. Anecdotally,
patients reported that the CPT-II, a task lasting much longer than any other task, was
demanding and required more sustained effort than the other tasks. The significant
relationships between the CPT-II subscales and the measures of cognitive complaints
may reflect the need for additional tasks that require sustained effort.
Clinical Implications
These results suggest, therefore, that caution should be used when interpreting
patients’ cognitive complaints. The overlap between cognitive complaints and
psychosocial measures raises the possibility that a patient reporting difficulty with
cognitive functioning may be experiencing psychological distress rather than impaired
cognitive functioning. The limited criterion validity of the FACT-Cog and EORTC-CF
also suggest that patients’ cognitive complaints are more likely to be related to deficits in
attention, than to deficits in memory, executive functioning, and motor coordination.
Future Directions
Future research should seek to refine the FACT-Cog through item reduction as
well as to factor analyze the FACT-Cog to provide support for the domain scores. In
addition, more research looking at the relationship of cognitive complaints to cognitive
performance is needed. Research utilizing a longitudinal design is important to
determine the temporal stability of cognitive complaints as well as to examine how
changes in cognitive performance relate to cognitive complaints. The small effects sizes
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found in this study suggest the need for research with larger sample sizes to have the
ability to detect significant difference for small effect sizes. Additionally, research
should be conducted with other clinical populations with high rates of impairment where
detection of relationships between objective and subjective aspects of cognitive
functioning may be more likely. Future research should include more demanding
neuropsychological tasks such as the CPT-II since evidence suggests a stronger
relationship between cognitive complaints and tasks requiring sustained effort. Finally,
neuropsychological tasks that have greater ecological validity, such as memory tasks that
requires recall over several days, should be used to assess the relationship between
cognitive performance and cognitive complaints.
In conclusion, the present study provides information about the validity and
reliability of a new measure to assess cognitive complaint in cancer patients, the FACTCog. Results demonstrated the internal consistency reliability of the FACT-Cog. The
concurrent validity of the FACT-Cog was supported by significant relationship to the
EORTC-CF. The convergent validity of the FACT-Cog was supported by the significant
relationships to measures of depression, fatigue, anxiety, mental well-being, physical
well-being, and neuroticism demonstrating the convergent validity of the measure. The
divergent validity of the FACT-Cog was supported by the lack of significant relationship
with a measure of extroversion. The criterion validity of the FACT-Cog was generally
not supported based on the limited number of significant correlations with
neuropsychological test scores. The FACT-cog did not demonstrate superior
psychometric properties than the EORTC-CF, a commonly used measure of cognitive
complaints. Future research is needed to reduce the number of items in the FACT-Cog
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and to factor analyze the FACT-Cog to provide support for the domain scores.
Additional research should also utilize a longitudinal design, be conducted with other
clinical populations, and include demanding neuropsychological tasks that require
sustained effort.
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Table 1
Demographic Characteristics of Sample (N = 82)
________________________________________________________________
Variable
_____
Mean age (SD)
52.91
(12.03)
Mean education (SD)
13.76
(2.30)
Estimated IQ (SD)
98.5
(15.30)
Gender
Male
Female

42
40

(51.2%)
(48.8%)

Ethnicity
White/Caucasian
Black/African American
Latino/Hispanic
Other

70
7
4
1

(85.4%)
(8.5%)
(4.9%)
(1.2%)

Marital Status
Single, never married
Married
Divorced
Widowed
Separated

4
65
9
3
1

(4.9%)
(79.3%)
(11.0%)
(3.7%)
(1.2%)

Employment status
Paid full-time employment
Paid part-time employment
On leave with pay
On leave without pay
Not employed – disabled
Not employed – retired
Not employed – Seeking work
Supported by others

23
5
7
8
17
11
2
9

(28.1%)
(6.1%)
(8.5%)
(9.8%)
(20.7%)
(13.4%)
(2.4%)
(11.0%)

4
7
16
21
18
12

(5.0%)
(8.8%)
(20.0%)
(26.3%)
(22.5%)
(15.0%)

Total household income*
Less than $ 10,000
$10,000 - $19,999
$20,000 - $ 39,999
$40,000 - $59,999
$60,000 - $100,000
Greater than $100,000
* Data missing for 4 participants
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Table 2
Clinical Characteristics of Sample (N = 82)
Variable
Evaluation
Six month follow-up
Twelve month follow-up

56
26

(68.3%)
(31.7%)

BMT Type
Autologous
Allogeneic

70
12

(85.4%)
(14.6%)

Diagnosis
Multiple Myeloma
Non Hodgkins Lymphoma
Acute Lymphocytic Leukemia
Hodgkins Lymphoma
Acute Myelogenous Leukemia
Breast Cancer
Testicular Cancer
Aplastic Anemia
Myelodysplasia
Chronic Myelogenous Leukemia
Amyloidosis

59
5
2
1
4
4
1
1
1
3
1

(72.0%)
(6.1%)
(2.4%)
(1.2%)
(4.9%)
(4.9%)
(1.2%)
(1.2%)
(1.2%)
(3.7%)
(1.2%)
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Table 3
Correlational Analyses of FACT-Cog and EORTC-CF with Demographic and Clinical
Variables

Total
Gender
Age
Estimated IQ (NART)
Years of Education
Race (White/Caucasian or
All Others)
Marital Status
Time Since Transplant
(6month or 12 month)
Type of Transplant

.31**
.03
.18
-.02
-.13

FACT-Cog
Cognitive IOF
.30**
.07
.15
-.03
-.17

.32**
.04
.13
-.03
-.12

EORTC-CF
QOL
.26*
-.03
.22*
.01
-.09

.22*
.09
.10
-.14
-.22*
.08
.08

.15
.03

.17
.01

.15
.06

.11
.02

-.07

-.08

-.07

-.05

* p < .05
**p < .01
IOF = Interference of Functioning
QOL = Quality of Life
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-.27**

Table 4
Correlational Analyses of FACT-Cog and EORTC-CF with Psychosocial Variables

Total
Depression (CES-D)
Fatigue (FSI)
Anxiety (STAI)
Mental Wellbeing (SF-36)
Physical Wellbeing (SF-36)
Extroversion (NEO)
Neuroticism (NEO)

FACT-Cog
Cognitive IOF

EORTC-CF
QOL

.50**** .45**** .44**** .52****
.53**** .45**** .49**** .58****
.36***
.33**
.31**
.39***
-.51**** -.46**** -.50**** -.50****
-.29**
-.27*
-.25*
-.32**
-.20
-.18
-.25*
-.14
.23*
.29**
.21*
.13

* p < .05
**p < .01
***p < .001
**** p < .0001
IOF = Interference of Functioning
QOL = Quality of Life
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.44****
.44****
.35***
-.48****
-.31***
-.30**
.14

Table 5
Regression Analysis of the FACT-Cog Total Score
β
Demographic variables
Gender
Psychosocial variables
Fatigue (FSI)
Mental Well-being
(SF-36)
Neuroticism (NEO)
Anxiety (STAI)
Depression (CES-D)
Physical Well-being
(SF-36)

R2 change

Cumulative R2

p value Uniqueness
Index

.201

.094

.094

.005

.037

.265
-.254

.257
.046

.357
.373

.0001
.020

.025
.018

.118
-.163
.150
-.050

.007
.003
.005
.002

.380
.383
.389
.389

.362
.557
.432
.667

.011
.008
.005
.002
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Table 6
Regression Analysis of the FACT-Cog Cognitive Domain
β
Demographic variables
Gender
Psychosocial variables
Mental Well-being
(SF-36)
Fatigue (FSI)
Neuroticism (NEO)
Anxiety (STAI)
Depression (CES-D)
Physical Well-being
(SF-36)

R2 change

Cumulative R2

p value Uniqueness
Index

.205

.091

.094

.006

.039

-.225

.183

.274

.0001

.014

.169
.219
-.229
.208
-.068

.023
.027
.006
.010
.003

.298
.325
.331
.340
.343

.111
.082
.425
.295
.575

.010
.036
.016
.009
.003
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Table 7
Regression Analysis of the FACT-Cog Interference of Functioning
β
Demographic variables
Gender
Psychosocial variables
Mental Well-being
(SF-36)
Fatigue (FSI)
Extroversion (NEO)
Anxiety (STAI)
Physical Well-being
(SF-36)
Depression (CES-D)

R2 change

Cumulative R2

p value Uniqueness
Index

.226

.100

.100

.004

.047

-.357

.222

.322

.0001

.037

.239
-.158
-.181
-.029

.029
.016
.012
.001

.351
.367
.379
.379

.065
.166
.232
.786

.021
.021
.011
.001

.047

.000

.380

.819

.001
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Table 8
Regression Analysis of the FACT-Cog Quality of Life Domain
β
Demographic variables
Gender
IQ (NART)
Psychosocial variables
Fatigue (FSI)
Mental Well-being
(SF-36)
Depression (CES-D)
Physical Well-being
(SF-36)
Anxiety (STAI)

R2 change

.127
.072

.099

.317
-.173

Cumulative R2

p value Uniqueness
Index

.099

.042
.087

.015
.004

.257
.027

.356
.383

.0001
.07

.033
.008

.138
-.042

.005
.001

.389
.389

.43
.73

.004
.001

-.033

.000

.390

.83

.000
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Table 9
Correlational Analyses of FACT-Cog and EORTC-CF with Neuropsychological Test
Performance (Continuous Measures)

Total Neuropsychological
Performance
Memory Domain
Executive Functioning
Domain
Motor Domain
Attention Domain

Total

FACT-Cog
Cognitive IOF

QOL

.06

.07

.07

.05

.11

.11
-.05

.11
-.12

.10
-.02

.08
.00

.05
-.03

-.18
.08

-.16
.11

-.17
.07

-.17
.04

-.11
.18

IOF = Interference of Functioning
QOL = Quality of Life
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EORTC-CF

Table 10
Correlation of FACT-Cog and EORTC-CF with Neuropsychological Test Scores
(Continuous Measures)
Total

FACT-Cog
Cognitive IOF

QOL

.07
.09

.08
.10

.08
.09

.05
.06

-.03
.04

-.19
-.11
.08

-.20
-.12
.04

-.18
-.09
.05

-.16
-.10
.13

-.09
-.08
-.03

.15
.14
.13
.15
.15
.13
.13

.12
.16
.16
.16
.18
.16
.18

.15
.14
.12
.14
.16
.12
.11

.17
.10
.10
.11
.10
.09
.08

.10
.15
.13
.13
.09
.01
.00

Executive Functioning Domain
Digit Symbol
Trails A
Trails B
COWA
Stroop

-.10
.03
-.01
.03
-.11

-.06
-.01
-.09
-.05
-.16

-.09
.06
.00
.05
-.06

-.12
.05
.07
.10
-.09

-.06
.02
.08
-.10
-.02

Motor Domain
Grooved Pegs
Dominant
Non-dominant

-.17
-.15

-.16
-.13

-.17
-.15

-.16
-.15

-.16
-.04

Attention Domain
CPT-II Subscales
Inattention
Impulsivity
Vigilance

.01
.12
.18

.04
.15
.17

.02
.12
.14

-.03
.07
.21*

Memory Domain
Logical Memory
Immediate
Delayed
Visual Reproduction
Immediate
Delayed
Recall
CVLT
Total
Short Delay Free
Short Delay Cued
Long Delay Free
Long Delay Cued
Recognition
Discrimination

*p<.05
IOF = Interference of Functioning; QOL = Quality of Life
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EORTC-CF

.17
.23*
.02

Table 11
Correlational Analyses of FACT-Cog and EORTC-CF with Neuropsychological Test
Performance (Impairment Classification)

Total Neuropsychological
Performance
Memory Domain
Executive Functioning
Domain
Motor Domain
Attention Domain

Total

FACT-Cog
Cognitive IOF

.01

.04

.03

-.05

.06

-.15
.03

-.18
.06

-.16
.00

-.08
.02

-.16
.12

.11
.08

.06
.02

.13
.04

.12
.16

.03
.10

IOF = Interference of Functioning
QOL = Quality of Life
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EORTC-CF
QOL

Table 12
Correlation of FACT-Cog and EORTC-CF with Neuropsychological Test Scores
(Impairment Classification)
FACT-Cog
Total
Cognitive IOF
Memory Domain
Logical Memory
Immediate
Delayed
Visual Reproduction
Immediate
Delayed
Recall
CVLT
Total
Short Delay Free
Short Delay Cued
Long Delay Free
Long Delay Cued
Recognition
Discrimination
Executive Functioning Domain
Digit Symbol
Trails A
Trails B
COWA
Stroop

EORTC-CF
QOL

-.10
-.05

-.09
-.11

-.11
-.07

-.10
.03

-.12
-.12

.15
.16
-.10

.15
.14
-.09

.14
.13
-.11

.12
.19
-.10

.13
.26*
-.12

-.14
-.14
-.18
-.19
-.19
-.16
-.14

-.18
-.18
-.22*
-.22*
-.21
-.16
-.15

-.12
-.12
-.18
-.16
-.16
-.14
-.13

-.10
-.10
-.12
-.18
-.17
-.15
-.11

-.15
-.15
-.15
-.15
-.15
.04
-.06

.07
.08
-.04
-.01
.01

.07
.08
-.04
.04
.03

.03
.02
-.05
-.01
-.03

.09
.13
-.01
-.06
.02

.07
.18
-.10
.18
-.10

Motor Domain
Grooved Pegs
Dominant
Non-dominant

.12
.14

.09
.07

.14
.17

.11
.15

.14
.08

Attention Domain
CPT-II Subscales
Inattention
Impulsivity
Vigilance

.16
.28**
.22*

.14
.23*
.18

.13
.24*
.16

.19
.33**
.29**

.26*
.30**
.20

*p<.05, **p<.01
IOF = Interference of Functioning; QOL = Quality of Life
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Table 13
Regression Analysis of the EORTC-CF Score
β
Demographic variables
Gender
Race (White or other)
Transplant (auto/allo)
Psychosocial variables
Mental Well-being
(SF-36)
Fatigue (FSI)
Extroversion (NEO)
Physical Well-being
(SF-36)
Anxiety (STAI)
Depression (CES-D)

R2 change

.152
-.137
-.260

.160

-.284

Cumulative R2

p value Uniqueness
Index

.160

.016
.150
.028

.021
.016
.057

.207

.367

.0001

.023

.198
-.193
-.078

.029
.034
.003

.396
.430
.433

.060
.039
.528

.014
.031
.004

-.059
.032

.001
.000

.434
.434

.728
.823

.001
.000
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale

Below is a list of statements that other people with your condition have said are
important. By circling one (1) number per line, please indicate how often each of
the following has occurred during the past 7 days.
Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times
a day

I have had trouble forming thoughts ....

0

1

2

3

4

My thinking has been unclear ..............
My thinking has been slow ..................
My thinking has been foggy.................
I have had trouble adding or
subtracting numbers in my head...........
I have made mistakes when writing
down phone numbers...........................
I have had trouble concentrating ..........
I have had trouble remembering the
name of a familiar person ....................
I have had trouble finding my way to
a familiar place ....................................
I have had trouble remembering
where I put things, like my keys or
my wallet.............................................
I have had trouble remembering
whether I did things I was supposed
to do, like taking a medicine or
buying something I needed ..................
I have had trouble remembering new
information, like phone numbers or
simple instructions ..............................
I have had trouble recalling the name
of an object while talking to someone
Words I wanted to use have seemed
to be on the “tip of my tongue” ............
I have had trouble finding the right
word(s) to express myself ....................

0
0
0
0

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued)

By circling one (1) number per line, please indicate how often each statement
has occurred during the past 7 days.

I have used the wrong word when I
referred to an object .................................
I have had trouble speaking fluently.........
I have had trouble saying what I mean in
conversations with others.........................
I have needed to keep a written list so I
would not forget things ............................
I have walked into a room and forgotten
what I meant to get or do there.................
I have needed medical instructions
repeated because I could not keep them
straight ....................................................
I have forgotten or accidentally missed
medical appointments ..............................
I have had to work really hard to pay
attention or else I would forget what I
was doing ................................................
I have had to work really hard to pay
attention or I would make a mistake.........
I have forgotten names of people soon
after being introduced ..............................
My reactions in everyday situations
have been slow ........................................
Other people have noticed that I had
problems remembering information .........
Other people have noticed that I had
problems speaking clearly........................
Other people have noticed that I had
problems thinking clearly ........................

Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times
a day

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued)

By circling one (1) number per line, please indicate how often each statement
has occurred during the past 7 days.

It has seemed like my brain was not
working as well as usual ....................
I have had to work harder than usual
to remember things .............................
I have had to work harder than usual
to keep track of what I was doing........
My thinking has been slower than
usual ...................................................
I have had to work harder than usual
to express myself clearly.....................
I have had more problems conversing
with others ..........................................

Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times
a day

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued)

Please answer the remaining questions with regard to all the above concerns
that you have identified.

I have hidden these problems so
others would not notice .......................
I have been upset about these
problems.............................................
I have told others about these
problems.............................................
These problems have interfered with
my ability to work...............................
These problems have interfered with
my ability to do things I enjoy.............
I have tried to do things (like writing
lists or keeping a calendar) so these
problems would not interfere ..............
These problems have been frustrating
for me .................................................
These problems have interfered with
the quality of my life...........................

Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times
a day

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4
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Appendix A: Functional Assessment of Cancer Therapy Cognitive Scale (Continued)

Please answer the remaining questions with regard to all the above concerns
that you have identified.

I have hidden these problems so
others would not notice ....................
I have been upset about these
problems..........................................
I have told others about these
problems..........................................
These problems have interfered
with my ability to work....................
These problems have interfered
with my ability to do things I enjoy..
I have tried to do things (like
writing lists or keeping a calendar)
so these problems would not
interfere ...........................................
These problems have been
frustrating for me .............................
These problems have interfered
with the quality of my life ................

Not
at all

A little
bit

Somewhat

Quite
a bit

Very
much

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4
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Appendix B: EORTC QLQ-C30 Cognitive Functioning Scale
Directions: For each item below, please check the ONE box.

During the past week:
Not at
all
1. Have you had difficulty in concentrating
on things, like reading a newspaper or
watching television?
2. Have you had difficulty remembering
things?
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A
little

Quite
a bit

Very
much

Appendix C: Center for Epidemiological Studies – Depression
For each statement below, make an “X” in the box which best describes how often you
felt or behaved this way-- DURING THE PAST WEEK, INCLUDING TODAY.
Rarely or
None of
of the time
(< 1 day)

Some or
a little
of the time
(1-2 days)

Occasionally
Most or
or a moderate all of
amount of the the time
(3-4 days)
(5-7 days)

DURING THE PAST WEEK:
1.

I was bothered by things that
usually don't bother me............................ r

r

r

r

2.

I did not feel like eating; my
appetite was poor .................................... r

r

r

r

3.

I felt that I could not shake off the
blues even with help from my
family or friends ....................................... r

r

r

r

4.

I felt that I was just as good as
other people............................................. r

r

r

r

5.

I had trouble keeping my mind on
what I was doing ...................................... r

r

r

r

6.

I felt depressed ........................................ r

r

r

r

7.

I felt that everything I did was
an effort ................................................... r

r

r

r

8.

I felt hopeful about the future ................... r

r

r

r

9.

I thought my life had been a failure .......... r

r

r

r

10.

I felt fearful............................................... r

r

r

r

11.

My sleep was restless.............................. r

r

r

r

12.

I was happy ............................................. r

r

r

r

13.

I talked less than usual ............................ r

r

r

r

14.

I felt lonely ............................................... r

r

r

r

15.

People were unfriendly ............................ r

r

r

r

16.

I enjoyed life ............................................ r

r

r

r

17.

I had crying spells .................................... r

r

r

r

18.

I felt sad................................................... r

r

r

r

19.

I felt that people disliked me..................... r

r

r

r

20.

I could not “get going” .............................. r

r

r

r
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Appendix D: State-Trait Anxiety Inventory
DIRECTIONS: A number of statements which people have used to describe
themselves are given below. Read each statement and then check the
appropriate box to the right of the statement to indicate how you feel right now,
that is, at this moment. There are no right or wrong answers. Do not spend too
much time on any one statement but give the answer which seems to describe
your present feelings best.
NOT
AT ALL

SOMEWHAT

1. I feel calm.. ............................
2. I feel secure............................
3. I am tense. .............................
4. I feel strained..........................
5. I feel at ease...........................
6. I feel upset..............................
7. I am presently worrying
over possible misfortunes.......
8. I feel satisfied. ........................
9. I feel frightened.. ...................
10. I feel comfortable....................
11. I feel self-confident. ................
12. I feel nervous..........................
13. I am jittery...............................
14. I feel indecisive.......................
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MODERATELY
VERY
SO
MUCH SO

Appendix D: State-Trait Anxiety Inventory (Continued)
NOT
AT ALL

SOMEWHAT

15. I am relaxed. ..........................
16. I feel content...........................
17. I am worried. ..........................
18. I feel confused........................
19. I feel steady............................
20. I feel pleasant.........................
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MODERATELY
VERY
SO
MUCH SO

Appendix E: Fatigue Symptom Inventory
PART I. For each of the following, circle the one number that best indicates how that item applies to you.
1. Rate your level of fatigue on the day you felt most fatigued during the past week.
0
Not at all
fatigued

1

2

3

4

5

6

7

8

9
10
As fatigued
as I could be

2. Rate your level of fatigue on the day you felt least fatigued during the past week.
0
Not at all
fatigued

1

2

3

4

5

6

7

8

9
10
As fatigued
as I could be

3. Rate your level of fatigue on the average in the last week.
0
Not at all
fatigued

1

2

3

4

5

6

7

8

9
10
As fatigued
as I could be

4

5

6

7

8

9
10
As fatigued
as I could be

4. Rate your level of fatigue right now.
0
Not at all
fatigued

1

2

3

5. Rate how much, in the past week, fatigue interfered with your general level of activity:
0
1
No
interference

2

3

4

5

6

7

8

9

10
Extreme
interference

6. Rate how much, in the past week, fatigue interfered with your ability to bathe and dress
yourself:
0
1
No
interference

2

3

4

5

6

7

8

9

7. Rate how much, in the past week, fatigue interfered with your normal work activity
both work outside the home and housework):
0
1
No
interference

2

3

4

5
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6

7

8

10
Extreme
interference
(includes

9

10
Extreme
interference

Appendix E: Fatigue Symptom Inventory (Continued)
8. Rate how much, in the past week, fatigue interfered with your ability to concentrate:
0
1
No
interference

2

3

4

5

6

7

8

9

10
Extreme
interference

9. Rate how much, in the past week, fatigue interfered with your relations with other people:
0
1
No
interference

2

3

4

5

6

7

8

9

10
Extreme
interference

8

9

10
Extreme
interference

8

9

10
Extreme
interference

9

10
The entire
day

10. Rate how much, in the past week, fatigue interfered with your enjoyment of life:
0
1
No
interference

2

3

4

5

6

7

11. Rate how much, in the past week, fatigue interfered with your mood:
0
1
No
interference

2

3

4

5

6

7

12. Indicate how many days, in the past week, you felt fatigued for any part of the day:
0
Days

1

2

3

4

5

6

7
Days

13. Rate how much of the day, on average, you felt fatigued in the past week:
0
None of
the day

1

2

3

4

5

6

7

8

14. Indicate which of the following best describes the daily pattern of your fatigue in the past
week:
0
Not at all
fatigued

1
Worse in
the morning

2
Worse in the
afternoon
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3
Worse in
the evening

4
No consistent daily
pattern of fatigue

Appendix F: Medical Outcome SF-36 Health Survey
INSTRUCTIONS: This survey asks for your views about your health. This information will
help keep track of how you feel and how well you are able to do your usual activities. Answer
every question by marking the answer as indicated. If you are unsure about how to answer a
question, please give the best answer you can.
1.

In general, would you say your health is (check one):
Excellent

2.

r

Very good

r

Good

r

Fair

r

r

Compared to one year ago, how would you rate your health in general now? (check one)
Much better now than one year ago
Somewhat better now than one year ago
About the same as one year ago
Somewhat worse now than one year ago
Much worse than one year ago

3.

Poor

r
r
r
r
r

The following items are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much? (check appropriate answer)
Yes,
Yes,
No, Not
Limited a lot Limited a little limited at all
a. Vigorous activities, such as
running, lifting heavy objects,
participating in strenuous sports

r

r

r

b. Moderate activities, such as
moving a table, pushing a
vacuum cleaner, bowling, or
playing golf

r

r

r

r

r

r

d. Climbing several flights of
stairs

r

r

r

e. Climbing one flight of stairs

r
r
r
r
r

r
r
r
r
r

r
r
r
r
r

c. Lifting or carrying groceries

f. Bending, kneeling or stooping
g. Walking more than a mile
h. Walking several blocks
i. Walking one block
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Appendix F: Medical Outcome SF-36 Health Survey (Continued)
4.

During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of your physical health? (check yes or no for
each)
Yes
No
a. Cut down the amount of time you spent on work or
other activities
b. Accomplished less than you would like
c. Were limited in the kind of work or other activities
d. Had difficulty performing the work or other activities (for
example, it took extra effort)

5.

Yes

No

a. Cut down the amount of time you spent on work or other
activities

r

r

b. Accomplished less than you would like

r
r

r
r

During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbors, or groups?
(check one)
Not at all
Slightly
Moderately
Quite a bit
Extremely

7.

r
r
r
r

During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result any emotional problems (such as feeling
depressed or anxious)? (check yes or no for each)

c. Didn't do work or other activities as carefully as usual
6.

r
r
r
r

r
r
r
r
r

How much bodily pain have you had during the past 4 weeks? (check one)
None
Very mild
Mild
Moderate
Severe
Very severe

r
r
r
r
r
r
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Appendix F: Medical Outcome SF-36 Health Survey (Continued)
8.

During the past 4 weeks, how much did pain interfere with your normal work (including
both work outside the home and housework)? (check one)
Not at all
A little bit
Moderately
Quite a bit
Extremely

9.

r
r
r
r
r

These questions are about how you feel and how things have been with you
during the past 4 weeks. For each question, please give the one answer that
comes closest to the way you have been feeling. (check appropriate answer).
All of
the
time

Most
of the
time

A good
bit of
the time

Some
of the
time

A little
of the
time

None
of the
time

r

r

r

r

r

r

r

r

r

r

r

r

c. Have you felt so down in the
dumps that nothing could cheer
you up?

r

r

r

r

r

r

d. Have you felt calm and
peaceful?

r

r

r

r

r

r

e. Did you have a lot of energy?

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r

r

r

r

r

r

How much of the time
during the past 4 weeks:
a. Did you feel full of pep?
b. Have you been a very
nervous person?

f. Have you felt downhearted
and blue?
g. Did you feel worn out?
h. Have you been a happy
person?
i. Did you feel tired?
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Appendix F: Medical Outcome SF-36 Health Survey (Continued)
10.

During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with friends,
relatives, etc.)? (check one)
All of the time
Most of the time

r
r

r
A little of the time r

Some of the time

None of the time

11.

r

How TRUE or FALSE is each of the following statements for you? (check
appropriate answer)

a. I seem to get sick a little easier
than other people
b. I am as healthy as anybody I
know
c. I expect my health to get worse
d. My health is excellent

Definitely
true

Mostly
true

Don't
know

Mostly
false

Definitely
false

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r

r
r
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Appendix G: NEO – Five-Factor Inventory
Instructions: This questionnaire contains 60 statements. Read each statement carefully.
For each statement, check the box that goes with the response that best represents your
opinion. Check only one box for each statement.
Strongly
Disagree

Disagree

Strongly
Neutral Agree Agree

1.

I am not a worrier ................................................. r....

r

r

2.

I like to have a lot of people around me .............. r

r

r

r

r

3.

I don’t like to waste my time daydreaming ........... r

r

r

r

r

4.

I try to be courteous to everyone I meet ................ r

r

r

r

r

5.

I keep my belongings clean and neat .................... r

r

r

r

r

6.

I often feel inferior to others................................. r

r

r

r

r

7.

I laugh easily

................................................... r

r

r

r

r

8.

Once I find the right way to do something,
I stick to it
................................................... r

r

r

r

r

I often get into arguments with my family
and co-workers ................................................... r

r

r

r

r

10. I’m pretty good about pacing myself
so as to get things done on time ............................. r

r

r

r

r

11. When I am under a great deal of stress,
sometimes I feel like I’m going to pieces .............. r

r

r

r

r

12. I don’t consider myself especially
“light-hearted.” ................................................... r

r

r

r

r

13. I am intrigued by the patterns I find in
art and nature ................................................... r

r

r

r

r

14. Some people think I’m selfish and egotistical ........ r

r

r

r

r

15. I am not a very methodical person ......................... r

r

r

r

r

16. I rarely feel lonely or blue ..................................... r

r

r

r

r

9.
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Appendix G: NEO – Five-Factor Inventory (Continued)
Strongly
Disagree

Disagree

Strongly
Neutral Agree Agree

17. I really enjoy talking to people .............................. r

r

r

r

r

18. I believe letting students hear controversial
speakers can only confuse and mislead them ......... r

r

r

r

r

19. I would rather cooperate with others than .................
compete with them ................................................ r

r

r

r

r

20. I try to perform all the tasks assigned to
me conscientiously ................................................ r

r

r

r

r

21. I often feel tense and jittery ................................... r

r

r

r

r

22. I like to be where the action is ............................... r

r

r

r

r

23. Poetry has little or no effect on me ........................ r

r

r

r

r

24. I tend to be cynical and skeptical of others’
intentions
................................................... r

r

r

r

r

25. I have a clear set of goals and work toward
them in an orderly fashion ..................................... r

r

r

r

r

26. Sometimes I feel completely worthless .................. r

r

r

r

r

27. I usually prefer to do things alone.......................... r

r

r

r

r

28. I often try new and foreign foods ........................... r

r

r

r

r

29. I believe that most people will take
advantage of you if you let them............................. r

r

r

r

r

30. I waste a lot of time before settling down
to work
................................................... r

r

r

r

r

31. I rarely feel fearful or anxious ................................ r

r

r

r

r

32. I often feel as if I’m bursting with energy ............... r

r

r

r

r

33. I seldom notice the moods or feelings
that different environments produce ....................... r

r

r

r

r
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Appendix G: NEO – Five-Factor Inventory (Continued)
Strongly
Disagree

Disagree

Strongly
Neutral Agree Agree

34. Most people I know like me .................................. r

r

r

r

r

35. I work hard to accomplish my goals ...................... r

r

r

r

r

36. I often get angry at the way people treat me........... r

r

r

r

r

37. I am a cheerful, high-spirited person...................... r

r

r

r

r

38. I believe we should look to our religious...................
authorities for decisions on moral issues ................ r

r

r

r

r

39. Some people think of me as cold and
calculating
................................................... r

r

r

r

r

40. When I make a commitment, I can always
be counted on to follow through ............................ r

r

r

r

r

41. Too often, when things go wrong, I get ....................
discouraged and feel like giving up........................ r

r

r

r

r

42. I am not a cheerful optimist ................................... r

r

r

r

r

43. Sometimes when I am reading poetry ....
or looking at a work of art, I feel a chill
or wave of excitement ........................................... r

r

r

r

r

44. I’m hard-headed and tough-minded in
my attitudes
................................................... r

r

r

r

r

45. Sometimes I’m not as dependable or
reliable as I should be............................................ r

r

r

r

r

46. I am seldom sad or depressed ................................ r

r

r

r

r

47. My life is fast-paced.............................................. r

r

r

r

r

48. I have little interest in speculating on the
nature of the universe or the human
condition
................................................... r

r

r

r

r

49. I generally try to be thoughtful and considerate...... r

r

r

r

r
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Appendix G: NEO – Five-Factor Inventory (Continued)
Strongly
Disagree

Disagree

Strongly
Neutral Agree Agree

50. I am a productive person who always get the
job done
................................................... r

r

r

r

r

51. I often feel helpless and want someone
else to solve my problems ..................................... r

r

r

r

r

52. I am a very active person....................................... r

r

r

r

r

53. I have a lot of intellectual curiosity........................ r

r

r

r

r

54. If I don’t like people, I let them know it................. r

r

r

r

r

55. I never seem to be able to get organized ................ r

r

r

r

r

56. At times I have been so ashamed I just
want to hide
................................................... r

r

r

r

r

57. I would rather go my own way then be a
leader of others ................................................... r

r

r

58. I often enjoy playing with theories or
abstract ideas
................................................... r

r

r

r

r

59. If necessary, I am willing to manipulate
people to get what I want....................................... r

r

r

r

r

60. I strive for excellence in everything I do ................ r

r

r

r

r
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Appendix H: Background Interview
BACKGROUND INTERVIEW
Name:
MR#:
Age/DOB:
Handedness:
Race:
Marital Status:
Referring M.D.:
Date of Assessment:
ECOG (neuro only):
Karnofsky (neuro only):
History of Present Illness:
Diagnosis:
Diagnosis date:
BMT type:
Treatment so far?

Psychiatric History:
Have you ever seen a psychiatrist or other mental health professional? YES
Were you ever hospitalized for mental problems?
YES
Do you see a psychiatrist or other mental health professional now?
YES

NO
NO
NO

Current Medications:

Family Medical and Psychiatric History:
Is there a family history of cancer?
Are there family members with mental problems? Alcohol? Drugs? YES
98

NO

Appendix H: Background Interview (Continued)
Social History:
Who do you live with?
Where do you live?
Do you have any children?
How far did you go in school?
Any learning or attention problems as you were going through school?
Are you currently working? If not, when did you stop? Do you receive SSI or
disability?

How have you been sleeping?

How is your appetite?

Do you have a history of smoking? Alcohol consumption? Illicit drug use?

How much caffeine do you typically drink?
Do you have any other medical history of which we should be aware?

Do you have any history of head injury of loss of consciousness? Did this leave
any lasting effects?
Mental Status (any comments):
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Appendix H: Background Interview (Continued)
MENTAL STATUS EXAM
Appearance: (hygiene, dress, eye contact, posture, gait, level of consciousness,
attentiveness)
Does he/she appear his/her chronological age?

Attitude:

__ Cooperative

Activity:

__ Normal
__ Tremor

Mood:

__ Euthymic

__ Uncooperative
__ Psychomotor Retardation (or)
__ Dysphoric

__ Angry

__ Agitation

__ Anxious

__ Apathetic

Affect: (parameters: appropriateness, intensity, mobility, range reactivity)
__ Incongruent __ Flat
__ Tearful
__ Labile
__ Appropriate __ Normal
__ Full Range
Speech: (rate, flow, volume, clarity, spontaneity, word finding difficulties)
Thought Process:
__ Organized

__ Disorganized __ Tangential

Level of Consciousness: __ Alert __ Drowsy

__ Delirium

__ Loose Association
__ Stupor

Depression:
(2 week period)
__ Depressed Mood
__ Diminished interest/pleasure
__ Weight Loss
__ Insomnia/hyper
__ Psychomotor changes
__ Fatigue/Loss of energy
__ Worthlessness/guilt
__ Poor concentration/decision making
__ Thoughts of death/suicidal ideation
Adjustment:
(3 months)
__ Marked Distress
__Depressed

__ Impairment (social/occupational)
__ Anxiety
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__ Mixed

Appendix I: National Adult Reading Test
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Appendix J: Conners’ Continuous Performance Task-II
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Appendix J: Conners’ Continuous Performance Task-II (Continued)
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Appendix K: California Verbal Learning Test
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Appendix K: California Verbal Learning Test (Continued)
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Appendix K: California Verbal Learning Test (Continued)
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Appendix L: Logical Memory
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Appendix L: Logical Memory (Continued)
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Appendix L: Logical Memory (Continued)
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Appendix M: Visual Reproduction
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Appendix M: Visual Reproduction (Continued)
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Appendix N: Digit Symbol
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Appendix O: Trail Making Test A
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Appendix P: Trail Making Test B
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Appendix Q: Controlled Oral Word Association
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Appendix R: Stroop
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Appendix S: Grooved Pegboard
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